WO2021173933A1 - Formulations and uses thereof - Google Patents
Formulations and uses thereof Download PDFInfo
- Publication number
- WO2021173933A1 WO2021173933A1 PCT/US2021/019821 US2021019821W WO2021173933A1 WO 2021173933 A1 WO2021173933 A1 WO 2021173933A1 US 2021019821 W US2021019821 W US 2021019821W WO 2021173933 A1 WO2021173933 A1 WO 2021173933A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- essential oil
- oil
- formulation
- acid
- volume
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 537
- 238000009472 formulation Methods 0.000 title claims abstract description 275
- 239000012528 membrane Substances 0.000 claims abstract description 46
- 210000003463 organelle Anatomy 0.000 claims abstract description 31
- 210000001808 exosome Anatomy 0.000 claims abstract description 25
- 239000000341 volatile oil Substances 0.000 claims description 759
- 235000017803 cinnamon Nutrition 0.000 claims description 83
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 78
- 239000003240 coconut oil Substances 0.000 claims description 77
- 235000019864 coconut oil Nutrition 0.000 claims description 77
- 235000019198 oils Nutrition 0.000 claims description 74
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 73
- 239000000194 fatty acid Substances 0.000 claims description 73
- 229930195729 fatty acid Natural products 0.000 claims description 73
- 150000004665 fatty acids Chemical class 0.000 claims description 73
- 239000003921 oil Substances 0.000 claims description 73
- 240000003538 Chamaemelum nobile Species 0.000 claims description 71
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 71
- 239000010466 nut oil Substances 0.000 claims description 66
- 239000010776 emu oil Substances 0.000 claims description 62
- 235000018330 Macadamia integrifolia Nutrition 0.000 claims description 59
- 240000000912 Macadamia tetraphylla Species 0.000 claims description 59
- 235000003800 Macadamia tetraphylla Nutrition 0.000 claims description 59
- 239000004615 ingredient Substances 0.000 claims description 57
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 52
- 210000000170 cell membrane Anatomy 0.000 claims description 50
- 235000003717 Boswellia sacra Nutrition 0.000 claims description 47
- 235000012035 Boswellia serrata Nutrition 0.000 claims description 47
- 240000007551 Boswellia serrata Species 0.000 claims description 47
- 239000004863 Frankincense Substances 0.000 claims description 47
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 44
- 240000007311 Commiphora myrrha Species 0.000 claims description 43
- 235000006965 Commiphora myrrha Nutrition 0.000 claims description 43
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 43
- 229940088594 vitamin Drugs 0.000 claims description 42
- 229930003231 vitamin Natural products 0.000 claims description 42
- 235000013343 vitamin Nutrition 0.000 claims description 42
- 239000011782 vitamin Substances 0.000 claims description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 41
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 40
- 239000011707 mineral Substances 0.000 claims description 40
- 235000005979 Citrus limon Nutrition 0.000 claims description 39
- 244000131522 Citrus pyriformis Species 0.000 claims description 39
- 230000000975 bioactive effect Effects 0.000 claims description 39
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 36
- 244000223014 Syzygium aromaticum Species 0.000 claims description 36
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 36
- 244000042664 Matricaria chamomilla Species 0.000 claims description 35
- 235000004429 Matricaria chamomilla var recutita Nutrition 0.000 claims description 35
- 235000010254 Jasminum officinale Nutrition 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 30
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 30
- 240000004784 Cymbopogon citratus Species 0.000 claims description 30
- 235000017897 Cymbopogon citratus Nutrition 0.000 claims description 30
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 30
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 claims description 30
- 239000000787 lecithin Substances 0.000 claims description 30
- 229940067606 lecithin Drugs 0.000 claims description 30
- 235000010445 lecithin Nutrition 0.000 claims description 30
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 29
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 27
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 26
- 150000002632 lipids Chemical class 0.000 claims description 26
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 24
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 24
- 239000005642 Oleic acid Substances 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 24
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 23
- 229930003316 Vitamin D Natural products 0.000 claims description 23
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 23
- 229930003427 Vitamin E Natural products 0.000 claims description 23
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 23
- 150000003904 phospholipids Chemical class 0.000 claims description 23
- 235000020238 sunflower seed Nutrition 0.000 claims description 23
- 235000019155 vitamin A Nutrition 0.000 claims description 23
- 239000011719 vitamin A Substances 0.000 claims description 23
- 235000019166 vitamin D Nutrition 0.000 claims description 23
- 239000011710 vitamin D Substances 0.000 claims description 23
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 23
- 229940046009 vitamin E Drugs 0.000 claims description 23
- 235000019165 vitamin E Nutrition 0.000 claims description 23
- 239000011709 vitamin E Substances 0.000 claims description 23
- 229940045997 vitamin a Drugs 0.000 claims description 23
- 229940046008 vitamin d Drugs 0.000 claims description 23
- 235000017304 Ruaghas Nutrition 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 22
- 229940074391 gallic acid Drugs 0.000 claims description 22
- 235000004515 gallic acid Nutrition 0.000 claims description 22
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 22
- 229940040064 ubiquinol Drugs 0.000 claims description 22
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 claims description 22
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 claims description 21
- 235000013421 Kaempferia galanga Nutrition 0.000 claims description 20
- 244000062241 Kaempferia galanga Species 0.000 claims description 20
- 235000011187 glycerol Nutrition 0.000 claims description 20
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 19
- 208000027418 Wounds and injury Diseases 0.000 claims description 19
- 229920002674 hyaluronan Polymers 0.000 claims description 19
- 229960003160 hyaluronic acid Drugs 0.000 claims description 19
- 244000166652 Cymbopogon martinii Species 0.000 claims description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 claims description 17
- 229940051810 licorice root extract Drugs 0.000 claims description 17
- 235000020725 licorice root extract Nutrition 0.000 claims description 17
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 17
- 235000013311 vegetables Nutrition 0.000 claims description 17
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 16
- 230000006378 damage Effects 0.000 claims description 16
- 230000001413 cellular effect Effects 0.000 claims description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 14
- 229930003268 Vitamin C Natural products 0.000 claims description 14
- 229960003966 nicotinamide Drugs 0.000 claims description 14
- 235000005152 nicotinamide Nutrition 0.000 claims description 14
- 239000011570 nicotinamide Substances 0.000 claims description 14
- 239000011718 vitamin C Substances 0.000 claims description 14
- 235000019154 vitamin C Nutrition 0.000 claims description 14
- 108010024636 Glutathione Proteins 0.000 claims description 12
- 229960003180 glutathione Drugs 0.000 claims description 12
- 210000002374 sebum Anatomy 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 244000183685 Citrus aurantium Species 0.000 claims description 11
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 11
- 241000378544 Melaleuca quinquenervia Species 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 208000014674 injury Diseases 0.000 claims description 11
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 10
- 229940069445 licorice extract Drugs 0.000 claims description 10
- 240000002319 Citrus sinensis Species 0.000 claims description 9
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 9
- 229940106189 ceramide Drugs 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 7
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 7
- 235000020778 linoleic acid Nutrition 0.000 claims description 7
- 235000019488 nut oil Nutrition 0.000 claims description 7
- 239000004006 olive oil Substances 0.000 claims description 7
- 235000008390 olive oil Nutrition 0.000 claims description 7
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 6
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 6
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 6
- 230000004064 dysfunction Effects 0.000 claims description 6
- 210000005260 human cell Anatomy 0.000 claims description 6
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- 235000021314 Palmitic acid Nutrition 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 claims description 5
- 229960004705 kojic acid Drugs 0.000 claims description 5
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 claims description 3
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 claims description 3
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims description 3
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims description 3
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims description 3
- 244000062250 Kaempferia rotunda Species 0.000 claims description 3
- 235000013422 Kaempferia rotunda Nutrition 0.000 claims description 3
- 235000021360 Myristic acid Nutrition 0.000 claims description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 3
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 claims description 3
- 235000019486 Sunflower oil Nutrition 0.000 claims description 3
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 claims description 3
- 235000021322 Vaccenic acid Nutrition 0.000 claims description 3
- BJRNKVDFDLYUGJ-ZIQFBCGOSA-N alpha-Arbutin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-ZIQFBCGOSA-N 0.000 claims description 3
- 229940033280 alpha-arbutin Drugs 0.000 claims description 3
- 229940114079 arachidonic acid Drugs 0.000 claims description 3
- 235000021342 arachidonic acid Nutrition 0.000 claims description 3
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 claims description 3
- 229940108623 eicosenoic acid Drugs 0.000 claims description 3
- BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 claims description 3
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-QXMHVHEDSA-N gadoleic acid Chemical compound CCCCCCCCCC\C=C/CCCCCCCC(O)=O LQJBNNIYVWPHFW-QXMHVHEDSA-N 0.000 claims description 3
- 239000002600 sunflower oil Substances 0.000 claims description 3
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 claims description 3
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 claims description 2
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 2
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 239000001585 thymus vulgaris Substances 0.000 claims description 2
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 claims description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims 4
- 240000005385 Jasminum sambac Species 0.000 claims 3
- 244000004281 Eucalyptus maculata Species 0.000 claims 2
- 240000002657 Thymus vulgaris Species 0.000 claims 1
- 125000005395 methacrylic acid group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 126
- 238000002360 preparation method Methods 0.000 abstract description 27
- 238000011282 treatment Methods 0.000 abstract description 19
- 238000000034 method Methods 0.000 abstract description 7
- 241000723347 Cinnamomum Species 0.000 description 79
- 208000002193 Pain Diseases 0.000 description 52
- 230000036407 pain Effects 0.000 description 52
- 239000000126 substance Substances 0.000 description 46
- 210000004379 membrane Anatomy 0.000 description 43
- 150000001875 compounds Chemical class 0.000 description 42
- 210000003491 skin Anatomy 0.000 description 39
- 235000010755 mineral Nutrition 0.000 description 38
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 36
- 244000166124 Eucalyptus globulus Species 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 33
- 235000001014 amino acid Nutrition 0.000 description 33
- 150000001413 amino acids Chemical class 0.000 description 33
- 230000006870 function Effects 0.000 description 32
- 230000017423 tissue regeneration Effects 0.000 description 31
- 240000006859 Jasminum officinale Species 0.000 description 29
- 239000000284 extract Substances 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 235000002639 sodium chloride Nutrition 0.000 description 25
- 239000011780 sodium chloride Substances 0.000 description 25
- 229930003799 tocopherol Natural products 0.000 description 25
- 239000011732 tocopherol Substances 0.000 description 25
- 206010061218 Inflammation Diseases 0.000 description 24
- 230000004054 inflammatory process Effects 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 229920006395 saturated elastomer Polymers 0.000 description 22
- 235000021313 oleic acid Nutrition 0.000 description 21
- 235000003392 Curcuma domestica Nutrition 0.000 description 19
- 244000008991 Curcuma longa Species 0.000 description 19
- 235000003373 curcuma longa Nutrition 0.000 description 19
- 235000013976 turmeric Nutrition 0.000 description 19
- -1 13%) Chemical class 0.000 description 18
- 229960001295 tocopherol Drugs 0.000 description 18
- 235000010384 tocopherol Nutrition 0.000 description 18
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 17
- 235000015112 vegetable and seed oil Nutrition 0.000 description 17
- 230000029663 wound healing Effects 0.000 description 17
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 17
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 17
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 17
- 229960000984 tocofersolan Drugs 0.000 description 16
- 230000000699 topical effect Effects 0.000 description 16
- 235000004835 α-tocopherol Nutrition 0.000 description 16
- 239000002076 α-tocopherol Substances 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 15
- 208000019901 Anxiety disease Diseases 0.000 description 14
- 230000036506 anxiety Effects 0.000 description 14
- 230000006872 improvement Effects 0.000 description 14
- 241000234314 Zingiber Species 0.000 description 13
- 235000006886 Zingiber officinale Nutrition 0.000 description 13
- 230000000843 anti-fungal effect Effects 0.000 description 13
- 230000000845 anti-microbial effect Effects 0.000 description 13
- 230000000840 anti-viral effect Effects 0.000 description 13
- 235000008397 ginger Nutrition 0.000 description 13
- 230000002159 abnormal effect Effects 0.000 description 12
- 201000004624 Dermatitis Diseases 0.000 description 11
- 208000002260 Keloid Diseases 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 11
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 210000001117 keloid Anatomy 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- 208000031226 Hyperlipidaemia Diseases 0.000 description 10
- 201000004681 Psoriasis Diseases 0.000 description 10
- 208000010668 atopic eczema Diseases 0.000 description 10
- 231100000241 scar Toxicity 0.000 description 10
- 241001474374 Blennius Species 0.000 description 9
- 206010009900 Colitis ulcerative Diseases 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 9
- 208000001145 Metabolic Syndrome Diseases 0.000 description 9
- 201000006704 Ulcerative Colitis Diseases 0.000 description 9
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 9
- 208000002551 irritable bowel syndrome Diseases 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 201000004384 Alopecia Diseases 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 241000202726 Bupleurum Species 0.000 description 8
- 208000011231 Crohn disease Diseases 0.000 description 8
- 208000010201 Exanthema Diseases 0.000 description 8
- 241000227647 Fucus vesiculosus Species 0.000 description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 8
- 206010023330 Keloid scar Diseases 0.000 description 8
- 208000018737 Parkinson disease Diseases 0.000 description 8
- 235000017826 Thymus zygis Nutrition 0.000 description 8
- 244000157222 Thymus zygis Species 0.000 description 8
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 8
- 208000029078 coronary artery disease Diseases 0.000 description 8
- 201000005884 exanthem Diseases 0.000 description 8
- 229940102465 ginger root Drugs 0.000 description 8
- 201000006417 multiple sclerosis Diseases 0.000 description 8
- 210000002985 organ of corti Anatomy 0.000 description 8
- 206010037844 rash Diseases 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 239000001841 zingiber officinale Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 208000010228 Erectile Dysfunction Diseases 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 208000007101 Muscle Cramp Diseases 0.000 description 7
- 206010049816 Muscle tightness Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 210000004907 gland Anatomy 0.000 description 7
- 210000004209 hair Anatomy 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 201000001881 impotence Diseases 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 235000019149 tocopherols Nutrition 0.000 description 7
- 239000008158 vegetable oil Substances 0.000 description 7
- 239000001243 zingiber officinale rosc. root absolute Substances 0.000 description 7
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 7
- 244000205574 Acorus calamus Species 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 235000011996 Calamus deerratus Nutrition 0.000 description 6
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 6
- 240000000560 Citrus x paradisi Species 0.000 description 6
- 241000190633 Cordyceps Species 0.000 description 6
- 241001327300 Cymbopogon schoenanthus Species 0.000 description 6
- 241000233866 Fungi Species 0.000 description 6
- 241000208152 Geranium Species 0.000 description 6
- 239000005909 Kieselgur Substances 0.000 description 6
- 208000029725 Metabolic bone disease Diseases 0.000 description 6
- 206010049088 Osteopenia Diseases 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 208000010340 Sleep Deprivation Diseases 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000003097 mucus Anatomy 0.000 description 6
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 6
- 208000033808 peripheral neuropathy Diseases 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000012049 topical pharmaceutical composition Substances 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 208000030760 Anaemia of chronic disease Diseases 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 5
- 241000951471 Citrus junos Species 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 206010028116 Mucosal inflammation Diseases 0.000 description 5
- 201000010927 Mucositis Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 241000205407 Polygonum Species 0.000 description 5
- 208000005793 Restless legs syndrome Diseases 0.000 description 5
- 241001503453 Rosalina Species 0.000 description 5
- 235000008089 Syzygium polyanthum Nutrition 0.000 description 5
- 240000000278 Syzygium polyanthum Species 0.000 description 5
- 235000009499 Vanilla fragrans Nutrition 0.000 description 5
- 244000290333 Vanilla fragrans Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 231100000360 alopecia Toxicity 0.000 description 5
- 208000022400 anemia due to chronic disease Diseases 0.000 description 5
- 239000010775 animal oil Substances 0.000 description 5
- 239000001359 coriandrum sativum l. oleoresin Substances 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 235000020708 ginger extract Nutrition 0.000 description 5
- 229940002508 ginger extract Drugs 0.000 description 5
- 210000002768 hair cell Anatomy 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 201000001119 neuropathy Diseases 0.000 description 5
- 230000007823 neuropathy Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 240000002234 Allium sativum Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 208000009079 Bronchial Spasm Diseases 0.000 description 4
- 208000014181 Bronchial disease Diseases 0.000 description 4
- 206010006482 Bronchospasm Diseases 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 244000037364 Cinnamomum aromaticum Species 0.000 description 4
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 4
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 4
- 235000002320 Citrus hystrix Nutrition 0.000 description 4
- 240000000981 Citrus hystrix Species 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 239000005639 Lauric acid Substances 0.000 description 4
- 244000062730 Melissa officinalis Species 0.000 description 4
- 235000014749 Mentha crispa Nutrition 0.000 description 4
- 244000078639 Mentha spicata Species 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 208000034189 Sclerosis Diseases 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 240000006909 Tilia x europaea Species 0.000 description 4
- 235000011941 Tilia x europaea Nutrition 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 244000078534 Vaccinium myrtillus Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 229920002770 condensed tannin Polymers 0.000 description 4
- 208000007784 diverticulitis Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 238000013265 extended release Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000004611 garlic Nutrition 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 229910021505 gold(III) hydroxide Inorganic materials 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 208000002741 leukoplakia Diseases 0.000 description 4
- 201000011486 lichen planus Diseases 0.000 description 4
- 239000004571 lime Substances 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229940124583 pain medication Drugs 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000002105 tongue Anatomy 0.000 description 4
- 102000035160 transmembrane proteins Human genes 0.000 description 4
- 108091005703 transmembrane proteins Proteins 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 3
- 208000015943 Coeliac disease Diseases 0.000 description 3
- 206010010741 Conjunctivitis Diseases 0.000 description 3
- 208000034656 Contusions Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 208000001640 Fibromyalgia Diseases 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 240000002262 Litsea cubeba Species 0.000 description 3
- 235000012854 Litsea cubeba Nutrition 0.000 description 3
- 206010025282 Lymphoedema Diseases 0.000 description 3
- 235000019493 Macadamia oil Nutrition 0.000 description 3
- 235000010654 Melissa officinalis Nutrition 0.000 description 3
- 244000246386 Mentha pulegium Species 0.000 description 3
- 235000016257 Mentha pulegium Nutrition 0.000 description 3
- 235000004357 Mentha x piperita Nutrition 0.000 description 3
- 206010029412 Nightmare Diseases 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 3
- 241000018646 Pinus brutia Species 0.000 description 3
- 235000011613 Pinus brutia Nutrition 0.000 description 3
- 208000008765 Sciatica Diseases 0.000 description 3
- 206010040799 Skin atrophy Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 3
- 206010048222 Xerosis Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 208000029650 alcohol withdrawal Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 208000002399 aphthous stomatitis Diseases 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 210000000270 basal cell Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000005282 brightening Methods 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 150000001783 ceramides Chemical class 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 210000004919 hair shaft Anatomy 0.000 description 3
- 208000014617 hemorrhoid Diseases 0.000 description 3
- 235000001050 hortel pimenta Nutrition 0.000 description 3
- 208000000069 hyperpigmentation Diseases 0.000 description 3
- 230000003810 hyperpigmentation Effects 0.000 description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 206010024217 lentigo Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000944 linseed oil Substances 0.000 description 3
- 235000021388 linseed oil Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000002502 lymphedema Diseases 0.000 description 3
- 239000010469 macadamia oil Substances 0.000 description 3
- 208000004396 mastitis Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 210000000110 microvilli Anatomy 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 229940097496 nasal spray Drugs 0.000 description 3
- 239000007922 nasal spray Substances 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 108091008695 photoreceptors Proteins 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- 210000004918 root sheath Anatomy 0.000 description 3
- 201000004700 rosacea Diseases 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000002363 skeletal muscle cell Anatomy 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 210000004500 stellate cell Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 210000000106 sweat gland Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000206761 Bacillariophyta Species 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 235000018793 Cymbopogon martinii Nutrition 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 240000001238 Gaultheria procumbens Species 0.000 description 2
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 235000004412 Jasminum grandiflorum Nutrition 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 244000179970 Monarda didyma Species 0.000 description 2
- 235000010672 Monarda didyma Nutrition 0.000 description 2
- 102400001103 Neurotensin Human genes 0.000 description 2
- 101800001814 Neurotensin Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010031009 Oral pain Diseases 0.000 description 2
- 102400000050 Oxytocin Human genes 0.000 description 2
- 101800000989 Oxytocin Proteins 0.000 description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 244000294611 Punica granatum Species 0.000 description 2
- 235000014360 Punica granatum Nutrition 0.000 description 2
- 241000494043 Ravensara Species 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 235000011034 Rubus glaucus Nutrition 0.000 description 2
- 244000235659 Rubus idaeus Species 0.000 description 2
- 235000009122 Rubus idaeus Nutrition 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 206010064127 Solar lentigo Diseases 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 229930003537 Vitamin B3 Natural products 0.000 description 2
- 241000070618 Zanthoxylum coreanum Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 210000000411 amacrine cell Anatomy 0.000 description 2
- 210000002255 anal canal Anatomy 0.000 description 2
- 230000003255 anti-acne Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002141 anti-parasite Effects 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 208000034526 bruise Diseases 0.000 description 2
- 208000020670 canker sore Diseases 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000010628 chamomile oil Substances 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 239000010462 extra virgin olive oil Substances 0.000 description 2
- 235000021010 extra-virgin olive oil Nutrition 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000005467 galactogogue Substances 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 229940087603 grape seed extract Drugs 0.000 description 2
- 235000002532 grape seed extract Nutrition 0.000 description 2
- 235000013761 grape skin extract Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000000917 hyperalgesic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003093 intracellular space Anatomy 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004699 muscle spindle Anatomy 0.000 description 2
- 108091008709 muscle spindles Proteins 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000000720 neurosecretory effect Effects 0.000 description 2
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 210000002394 ovarian follicle Anatomy 0.000 description 2
- 229960001723 oxytocin Drugs 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 210000005238 principal cell Anatomy 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 210000000449 purkinje cell Anatomy 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- NNNVXFKZMRGJPM-KHPPLWFESA-N sapienic acid Chemical compound CCCCCCCCC\C=C/CCCCC(O)=O NNNVXFKZMRGJPM-KHPPLWFESA-N 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000001779 taste bud Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- 230000001720 vestibular Effects 0.000 description 2
- 235000019160 vitamin B3 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 239000001717 vitis vinifera seed extract Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063746 Accidental death Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 241001367053 Autographa gamma Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 241000284156 Clerodendrum quadriloculare Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 206010052805 Drug tolerance decreased Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 208000036993 Frustration Diseases 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 235000019479 German chamomile oil Nutrition 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- 244000208060 Lawsonia inermis Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000003752 Lipocalin 1 Human genes 0.000 description 1
- 108010057281 Lipocalin 1 Proteins 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 101710137760 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102400001357 Motilin Human genes 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 1
- 206010064470 Muscle swelling Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 210000004460 N cell Anatomy 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028740 Nasal dryness Diseases 0.000 description 1
- 206010028741 Nasal inflammation Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 102400000319 Oxyntomodulin Human genes 0.000 description 1
- 101800001388 Oxyntomodulin Proteins 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 108010047320 Pepsinogen A Proteins 0.000 description 1
- 101800001672 Peptide YY(3-36) Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 206010037884 Rash pruritic Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 description 1
- 241000246358 Thymus Species 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 206010044708 Trypanosomal infections Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000949456 Zanthoxylum Species 0.000 description 1
- 235000004417 Zanthoxylum alatum Nutrition 0.000 description 1
- 244000294617 Zanthoxylum alatum Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 210000002934 adrenergic neuron Anatomy 0.000 description 1
- 210000002383 alveolar type I cell Anatomy 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001099 anti-trypanosomal effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002947 bartholin's gland Anatomy 0.000 description 1
- 210000001084 basket cell Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000002228 beta-basophil Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000001342 boswellia carteri birdw. oil Substances 0.000 description 1
- 210000003888 boundary cell Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000001593 brown adipocyte Anatomy 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 210000000465 brunner gland Anatomy 0.000 description 1
- 210000002533 bulbourethral gland Anatomy 0.000 description 1
- 210000004438 cajal-retzius cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000001011 carotid body Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000000250 cementoblast Anatomy 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 235000019480 chamomile oil Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 108091008690 chemoreceptors Proteins 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 210000003737 chromaffin cell Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000001524 citrus aurantium oil Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000020197 coconut milk Nutrition 0.000 description 1
- 239000001555 commiphora myrrha gum extract Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 210000003239 corneal fibroblast Anatomy 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 1
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 229940073499 decyl glucoside Drugs 0.000 description 1
- 210000000243 deiters cell Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 210000005232 distal tubule cell Anatomy 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000001162 elastic cartilage Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000000968 fibrocartilage Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 210000003322 glomus cell Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003652 golgi cell Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 108091005708 gustatory receptors Proteins 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000002287 horizontal cell Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000000067 inner hair cell Anatomy 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 206010022694 intestinal perforation Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000002384 kidney collecting duct cell Anatomy 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 210000001756 lactotroph Anatomy 0.000 description 1
- 210000003644 lens cell Anatomy 0.000 description 1
- 210000001542 lens epithelial cell Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000000210 loop of henle Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 210000001730 macula densa epithelial cell Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000001502 melanotroph Anatomy 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 210000001237 metamyelocyte Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 210000003550 mucous cell Anatomy 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000001915 nurse cell Anatomy 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 210000004416 odontoblast Anatomy 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000004415 olfactory epithelial cell Anatomy 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000002380 oogonia Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 210000003889 oxyphil cell of parathyroid gland Anatomy 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 230000037325 pain tolerance Effects 0.000 description 1
- 210000003134 paneth cell Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 210000002655 parathyroid chief cell Anatomy 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 210000003658 parietal epithelial cell Anatomy 0.000 description 1
- 208000022823 partial androgen insensitivity syndrome Diseases 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000006919 peptide aggregation Effects 0.000 description 1
- 210000002951 peptidergic neuron Anatomy 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000000280 pituicyte Anatomy 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000004043 pneumocyte Anatomy 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000002248 primary sensory neuron Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 230000000272 proprioceptive effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000003728 serous cell Anatomy 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000001622 small lutein cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- NTYZDAJPNNBYED-UHFFFAOYSA-M sodium;2-(2-dodecanoyloxypropanoyloxy)propanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O NTYZDAJPNNBYED-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000001764 somatotrope Anatomy 0.000 description 1
- 210000004336 spermatogonium Anatomy 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004272 stretch cell Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000003172 sustentacular cell Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002489 tectorial membrane Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 210000002014 trichocyte Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 210000001213 vestibule labyrinth Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 210000001849 von ebner gland Anatomy 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000037366 wrinkle cream Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 210000001235 zona fasciculata Anatomy 0.000 description 1
- 210000003368 zona glomerulosa Anatomy 0.000 description 1
- 210000002327 zona reticularis Anatomy 0.000 description 1
- 108020001588 κ-opioid receptors Proteins 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- Healthy cell membranes serve as a barrier to the environment outside of the cell. They also serve as a hub, filtering and interpreting signals from the cell’s surroundings and translating external signals into a cellular response by directing changes in gene expression. Healthy cell membranes also send, receive, and coordinate signals to and from other cells, and can elicit responses in cells close by, or even in cells at the opposite end of the body.
- Disturbances in cell membrane function may manifest as dysregulated growth and proliferation (leading to diseases such as cancer, keloids, or psoriasis, among others); as a disrupted skin barrier (leading, for example, to eczema or a non-healing wound); as hormone dysregulation such as, for example, in diabetes, hyperlipidemia, and metabolic syndrome; as poor immune function; or as disrupted neuronal signaling such as, for example, in multiple sclerosis and Alzheimer’s Disease.
- One of the possible manifestations of impairments in cell membrane function is a decreased tolerance to pain and an increased predisposition to inflammation. Pain is defined as a sensation related to potential or actual damage in a bodily tissue (PMID 25722692).
- Pain is a multifaceted experience for the patient, involving both a physical response in the damaged structures or tissues (inflammation, swelling, increased muscle tension, and physical sensitization) as well as a secondary' emotional response to the pain itself (anger, frustration, anxiety, insomnia, and emotional sensitization).
- insomnia further decreases global pain tolerance, worsens inflammation, and increases abnormal muscle tension, pain and swelling, thus perpetuating a negative feedforward cycle of pain.
- NSAIDs non-steroidal anti-inflammatory drugs
- opioids bind to mu, delta or kappa opioid receptors, reducing neuronal excitability in the neurons carrying pain signals to the Central Nervous System (CNS) leading to less perceived pain (PMID 9202932) but do not address inflammation, local swelling, or muscle tension.
- CNS Central Nervous System
- NSAIDs are toxic to the kidneys, ears, and liver, and cany a significant risk for generalized bleeding as well as peptic ulcer formation. NSAIDs may also lead to a hyperalgesic state via multiple proposed mechanisms (PMID 25722692). Acetaminophen, the third major oral pain medication, is toxic to the liver and kidneys, and potentially increases risk of bleeding and peptic ulcers.
- NS AID creams have a potential to significantly increase the risk for bleeding, heart attacks, high blood pressure, stroke, peptic ulcers, and bowel perforation in addition to inhibiting tissue healing.
- Menthol-based creams are not practical for use in cold weather, or by patients with broken skin.
- Capsaicin and arnica creams cany a lesser risk of bleeding, heart attack, high blood pressure and stroke than NS AID creams, but still have a potential to cause skin irritation.
- none of the current topical pain medications penetrate further than the outermost layer of the epidermis, resulting in pain relief for superficial structures only, leaving the pain of underlying structures untreated.
- the effects of current topical pain medications typically wear off after a few hours, requiring repeated application.
- the present invention provides formulations capable of incorporating into existing cell membranes and restoring cell membrane composition and/or functionfs) and modulating therapeutic effectfs).
- the formulations comprise a mixture of fatty acids in specific ratios such that the formulation may cross, integrate, modulate, regulate, or restore a functionfs) of a membrane of a cell, an organelle or an exosome, and/or a function of cell and/or an organelle and/or an exosome.
- the formulations may, e.g., supply a componentfs) to correct a deficiency in a cell membrane composition.
- the formulation may also be formulated to reduce transmission of signals in and between the cells, e.g., to reduce signaling for pain, inflammation, excess oxidation, etc.
- the formulation may also be formulated to increase healthy stem cell response to injury while limiting abnormal proliferation, division and/or other unhealthy responses of ceils.
- the formulations may also be formulated to interfere with functions of ceil membranes of microbes, viruses, fungi, insects, and parasites thereby resulting in a destruction or inactivation of microbes, viruses, fungi, insects, and parasites or an inability of microbes, viruses, fungi, insects and parasites to infect or inhabit their hostfs).
- the fatty acids in the formulations may come from oil(s) and/or fats or may be individually incorporated into the mixture.
- the formulations may comprise other components, as, e.g., described in detail below.
- the ratio of the faty acids in the mixture and the formulations themselves are customizable, as for example, described in detail below, to address specific diseases, and/or root deficiencies, and/or restore a composition of a membrane of a cell, as well as the membrane of various organelles within a cell (e.g., a mammalian cell), and/or restore and/or improve cellular function(s).
- the formulations may allow, e.g., for 1) delivery of therapeutic materials directly into tissues and cells and/or 2) delivery?
- the incorporation of the formulation into a cell membrane may directly disrupt the lipid rafts housing clusters of pain transmembrane proteins which require being clustered together in order to signal for pain.
- a formulation in accordance with the invention generally comprises: (i) a base composition, and one or more additional ingredient(s) dispersed in the base composition such that the formulation has a fatty acid composition that is substantially similar to that of a membrane of a ceil, an organelle or an exosome.
- the fatty acid composition of the formulation renders the formulation capable of one or more of the following: crossing, integrating, modulating, regulating, or restoring the membrane’s function(s) and/or a function(s) of a cell, an organelle or an exosome.
- the base composition may include a lipid.
- a lipid may, e.g., be an oil or a mixture oils or another substance comprising fatty acids.
- a lipid may, e.g., be an essential oil or a mixture of essential oils.
- the base composition may comprise from about 40% to about 99% of the formulation by volume.
- the base composition comprises one or more oils.
- the one or more oils of the base composition may, e.g., be selected from a group consisting of emu oil, coconut oil, macadamia nut oil, high oleic sunflower seed oil, olive oil, and mixtures comprising two, three, four or five of the foregoing oils.
- the base composition comprises a mixture of emu oil, coconut oil and macadamia nut oil.
- the base composition comprises a mixture of high oleic sunflower seed oil, coconut oil and rnacadarnia nut oil.
- Emu oil may, e.g., comprise from 0% to about 99% of the base composition by volume.
- Coconut oil may, e.g., comprise medium chain triglycerides derived from coconut oil, and comprise from 0% to 95% of the base composition by volume.
- High oleic sunflower seed oil may, e.g., comprise from 0% to about 90% of the base composition by volume.
- Macadamia nut oil may, e.g., comprise from 0% to about 25% of the base composition by volume.
- Olive oil may, e.g., comprise from about 0% to about 80% of the base composition by volume.
- the base composition consists of medium chain triglycerides derived from coconut oil.
- oils and lipids can also be used in the formulations of the invention as long as they are combined in amounts that provide a base composition that has a fatty acid composition that is substantially similar as that of a membrane of a cell, an organelle or an exosome (or, in certain embodiments, a fatty acid composition that contains more oleic acid than that of a membrane of a cell, an organelle or an exosome), and renders the formulation capable of crossing, integration, modulation, regulation, or restoration of membrane’s function(s) and/or a function(s) of a cell and/or organelle and/or an exosome.
- the formulation may further comprise a biosilicate (e.g., a Food Grade Diatomaceous Earth (FDGE) biosilicate) or a plurality ofbiosiiicates (e.g., a plurality of FDGE biosilicates).
- FDGE Food Grade Diatomaceous Earth
- the biosilicate(s) may, e.g., extend a duration of a desired effeel(s) of the formulation.
- the formulation may be free from conventional drugs (i.e., substances approved by regulatory' authorities (e.g., US FDA) for treatment of diseases in humans).
- the formulations may also be free from preservatives.
- the one more additional ingredient(s) of the formulation may be selected from a group consisting of a phospholipid, a ceramide, cholesterol, a fatty acid, an oil, a vitamin, a mineral, a therapeutic agent, an exosome, or a combination of any of the foregoing.
- the one or more additional ingredient(s) in the formulation may be an essential oil or a mixture of essential oils or an exosome.
- the base composition and the one or more additional ingredient(s) may be included in the formulation in an effective amount, to reduce severity or alleviate a symptom of a disease, associated with an injury, damage or dysfunction of a cellular membrane or an organelle in a mammal.
- the disease associated with a dysfunction, injury of damage of a cellular membrane function may, e.g., be pain, eczema, psoriasis, erythema, a bum, a cut, a bruise, a boil, a scar, a keloid, a non-healing wound, acne, rosacea, an allergy, an arthritis, an arthralgia, cancer, a neuropathy, a metabolic syndrome, an infection, a canker sore, an ulcer, Ulcerative Colitis (UC), a mucositis, diverticulitis, celiac disease, a colitis, Crohn’s Disease (CD), Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) atherosclerosis, Alzheimer’s Disease (AD), Parkinson’s Disease (PD), gout, solar lentigo, senile lentigines, skin atrophy, Lichen Sclerosis (LS), Lichen Planus (LP), asthma, Chronic Ob
- the symptom of the disease may, e.g., be pain, inflammation, skin irritation, rash, a lesion, a wrinkle, hyperpigmentation, a keloid, a scar, pruritus, itching, indigestion, diarrhea, a cramp, cough, a bronchospasm, a discoloration, and combinations or two or more of the foregoing.
- the base composition and the additional ingredient(s) may also be included in the formulation in an amount that disrupts cellular membrane function (e.g., of a virus, bacteria, fungi, insect or parasite) or modulates a cellular membrane function to activate healthy response from a cell, its subcellular organelles, or a group of cells (as, e.g., in a tissue).
- the formulation may also be formulated to restore proper amounts of missing cell membrane components to facilitate healthy cell signaling.
- a formulation may, e.g., comprise (i) a base composition comprising a lipid comprising fatty acids, and (ii) one or more additional ingredient(s) dispersed in the base composition, the additional ingredient(s) selected from a group consisting of a phospholipid, a ceramide, cholesterol, a fatty acid, an oil, a vitamin, a mineral, a therapeutic agent, a bioactive ingredient, an exosome, or a combination of two or more of any of the foregoing, wherein the fatty acids in the base composition are of a type and in amounts that render a fatty acid composition of the base composition identical or substantially similar to a fatty acid composition of a cell membrane or a cell organelle of mammalian sebum, and the base composition comprises from about 30% to about 99% of the formulation by volume.
- the fatty acids may, e.g., be selected from a group consisting of myristic acid (C14:Q), lauric acid (02:0), palmitic acid (06:0), arachidonic acid (( ' 20:4 n-6), stearic acid (08:0), oleic acid (08:1 n-9), linoleic acid (08: 1 n-9), linoleic acid (Cl 8-3 n-9), crotomc acid (C4H602), myristoieic acid, palmitoleic (06:1) acid, sapienic acid (06:1 n-10), oleic acid (08: 1 n-9), elaidic acid or trans-oleic acid (08:1 n-9), vaccenic acid (08:1 n-7), gadoleic acid (C20:l n- 11), eicosenoic acid (C20: 1 n-9), erucic acid (C22:l n
- the fatty acid composition of the base composition may be identical or substantially similar to a fatty acid composition of the cell membrane of a human cell.
- the lipid could, e.g., be a mixture comprising coconut oil and macadamia nut oil and may further comprise emu oil and/or high oleic sunflower seed oil.
- the one or more additional ingredients may comprise a mixture of German chamomile oil, Roman chamomile oil, andixie chamomile oil, the mixture comprising from about 5% to about 30% of the formulation by volume.
- the formulation may also comprise a mixture of individual fatty acids, wherein the faty acids are combined in the mixture such that the mixture and/or formulation has a faty acid composition that is substantially the same (i.e., approximate) as that of non-diseased human skin and/or sebum and/or cell membranes.
- the fatty acids are combined such that the fatty acid composition of the mixture is substantially the same as that of human skin and/or sebum.
- the fatty acids are combined such that the composition of the mixture supplements components of a membrane of a cell, organelle or exosome which may be deficient in such components due to disease, poor diet, or another cause.
- the mixture may, e.g., comprise, in % by volume, from about 0% to about 40% ceramides (e.g., 13%), from about 5% to about 99% fatty acids (e.g., 47%), including, e.g., phospholipids such as phosphatidylcholine, sphingomyelin, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol; from about 0% to about 25% cholesterol (e.g., 7%), from about 0% to about 25% cholesterol esters (e.g., 2%), from about 0% to about 25% squalene (e.g., 11%), from about 0% to about 20% triglycerides (e.g., 3%), from about 5% to about 99% proteins (e.g., 47%), and from about 0% to about 30% wax esters (e.g., 17%).
- ceramides e.g., 13%)
- the mixture may also comprise myristic acid (04:0), ⁇ auric acid (C12:0), palmitic acid (06:0), arachidonic acid (020:4 n-6), stearic acid (Cl 8:0), oleic acid (08:1 n-9), linoleic acid (08: 1 n-9), linoleic acid (08-3 n-9), crotonic acid (CM ft ⁇ ), myristoleic acid, palmitoleie (06:1) acid, sapienic acid (06:1 n-10), oleic acid (08:1 n-9), elaidic acid or trans-oleic acid (08:1 n-9), vaccenic acid (08:1 n-7), gadoleic acid (C ' 20: i n- 11), eicosenoic acid (C20:l n-9), erucic acid (( ' 22: i n-9) nervonic acid (C24:l n
- the mixture may also comprise a composition that is sufficient to correct an imbalance in a membrane of a cell or a membrane of a cell organelle, e.g., supply deficient membrane component(s).
- oleic acid comprises greater than 50% (e.g., about 65%, about 70%, about 75%, about 80%, about 85%, or about 95%) of the fatty acid composition.
- higher concentrations of oleic acid is required to penetrate into the subcelluiar organelles (e.g., to directly influence cellular metabolism) than a cell membrane because the compounds must cross more than one set of cell membranes.
- the fatty acids may be incorporated into the formulations by themselves or in the form of oils, phospholipids or mixtures of lipids.
- the present invention is specifically directed in part to a formulation comprising a composition comprising palmitic acid, stearic acid, oleic acid, and linoleic acid, wherein the palmitic acid comprises from about 20% to about 75% of the composition by weight, the stearic acid comprises from about 11% to about 13% of the composition by weight, the oleic acid comprises from about 8% to about 31% of the composition by weight, the linoleic acid comprises from about 15% to about 23% of the formulation by weight, and the formulation is capable of crossing a ceil membrane and/or incorporating into a cell membrane and/or modulating a cell membrane composition and/or function.
- the mixture may comprise a fatty acid composition that is similar to that of a mammalian cell membrane (e.g., a human cell membrane), except that it contains more oleic acid that the mammalian cell.
- the concentration of oleic acid may be adjusted to facilitate different degrees of penetration for admixed compound(s).
- the formulation may comprise (i) a base composition comprising a lipid comprising fatty acids, and (ii) a mixture comprising clove essential oil, cinnamon essential oil, rosemary essential oil, eucalyptus essential oil, lemon essential oil, ravintsara essential oil, and cinnamon essential oil dispersed in the base composition, wherein the lipid comprises a mixture of high oleic sunflower seed oil, coconut oil, and macadamia nut oil, clove essential oil comprises from about 0.1% to 30% of the formulation by volume; cinnamon essential oil comprises from about 0.1% to 30% of the formulation by volume; rosemary essential oil comprises from about.
- the formulation may further comprise, by volume, from about 0.05% to about 20% frankincense essential oil and/or from about 1% to about 30% thyme essential oil.
- the formulation may also comprise, in % by volume, from about 1% to about 30% biosilicates, from about 0.04% to about 20% German chamomile essential oil, from about 1% to about 20% Neue chamomile essential oil, from about 0.04% to about 20% Roman chamomile essential oil, from about 0.04% to about 10% jasmine essential oil, from about 0,04% to about 10% lemongrass essential oil, from about 1% to about 10% coconut oil, from about 5% to about 4% macadamia oil, from about 10% to about 80% emu oil.
- the formulation may further comprise vitamin D, hyaluronic acid, vitamin E, vitamin A, glycerin, ubiquinol, myrrh essential oil, frankincense essential oil, German chamomile essential oil, Roman Chamomile essential oil, andixie chamomile essential oil.
- the formulation may further comprise a Food Grade Diatomaceous Earth (EDGE) biosi!icate(s).
- EDGE Food Grade Diatomaceous Earth
- the formulation may also comprise (i) a base composition comprising a lipid comprising fatty acids, and (ii) a mixture comprising German chamomile essential oil,ixie chamomile essential oil, Roman chamomile essential oil, frankincense essential oil, myrrh essential oil, jasmine essential oil, lemongrass essential oil, sw ⁇ eet orange essential oil, bitter orange essential oil, rosemary essential oil, galangal essential oil, xiang mao essential oil, palmarosa essential oil, neroli essential oil, licorice extract, lecithin, coconut oil; the mixture dispersed in the base composition, wherein the lipid comprises a mixture comprising emu oil, coconut oil and macadamia nut oil, the base composition comprises from about 50% to about 99% of the formulation by volume.
- the formulation may, e.g., comprise, in % by volume, from about 0.01% to about 3% German chamomile essential oil, about 0.01% to about 3%ixie chamomile essential oil, from about 0.01% to about 3% Roman chamomile essential oil, from about 0.01% to about 10% frankincense essential oil, from about 0.01% to about 10% myrrh essential oil, from about 0.01% to about 2% of jasmine essential oil, from about 0.01% to about 2% of lemongrass essential oil, from about 0.01% to about 3% sweet orange essential oil, from about 0.01% to about 3% bitter orange essential oil, from about 0.01 % to about 3% rosemary?
- the formulation may further comprise a Food Grade Diatomaceous Earth (EDGE) biosilicate.
- EDGE Food Grade Diatomaceous Earth
- Administration of the formulations described herein may result in a modulation of the ceil membrane composition and/or function, hi some of the embodiments, an administration of the formulations described herein may result in an alleviation of pain. In some of the embodiments, an administration of the formulations described herein may result in improved wound healing. In some of the embodiments, an administration of the formulations described herein may result in improvement or resolution of eczema. In some of the embodiments, an administration of the formulations described herein may result in an improvement or resolution of psoriasis. In some of the embodiments, an administration of the formulations described herein may result in an improvement in the appearance of scars. In some of the embodiments, an administration of the formulations described herein may result in an improved recovery?
- an administration of the formulations described herein may result in an improvement in endocrine function. In some of the embodiments, an administration of the formulations described herein may result in an improvement of a serum lipid profile (e.g., an increase in HDL and/or a decrease in LDL and/or a decrease in triglycerides). In some of the embodiments, an administration of the formulations described herein may result in improved circulation and improvement in symptoms of Raynaud’s phenomenon. In some of the embodiments, an administration of the formulations described herein may result in improvement in function of the nervous system.
- an administration of the formulations described herein may result in improved concentration. In some of the embodiments, an administration of the formulations described herein may result in improved appearance and quantity of hair. In some of the embodiments, an administration of the formulations described herein may result in appearance of skin health. In some of the embodiments, an administration of the formulations described herein may result in alleviation of or improvement in headaches. In some of the embodiments, an administration of the formulations described herein may result in improvement of abdominal pain and diarrhea associated with Inflammatory Bowel Disease (e.g., Crohn’s Disease, Ulcerative Colitis), and with Irritable Bowel Disease.
- Inflammatory Bowel Disease e.g., Crohn’s Disease, Ulcerative Colitis
- an administration of the formulation described herein may result in an improvement or alleviation of anxiety and/or depression. In some of the embodiments, an administration of the formulations described herein may result, in improvement in the experience of wearing a mask. In some of the embodiments, an administration of the formulations described herein may result in reduction in nausea. In some of the embodiments, an administration of the formulations described herein may result in improved mood. In some of the embodiments, an administration of the formulations described herein may result in decreased appetite. In some of the embodiments, an administration of the formulation described herein may result in improvement in insomnia. In some of the embodiments, an administration of the formulations described herein may result in improvement or alleviation of social anxiety in patients with social anxiety. In some of the embodiments, an administration of the formulations described herein may result in improvement of an infection of the skin, nail, or body part caused by fungus, bacteria or virus.
- the present invention specifically encompasses liquid formulations comprising a fatty acid composition substantially similar (i.e., approximate) to a fatty acid composition of healthy human skin and/or sebum.
- the invention provides a formulation comprising a mixture of oils (e.g., animal oils and/or vegetable oils).
- oils included in the mixtures of the present invention may be selected, e.g., from a group comprising or consisting of emu oil, German chamomile essential oil,ixie chamomile essential oil, Roman chamomile essential oil, coconut oil, macadamia oil, jojoba wax, lime essential oil, grapefruit essential oil, blackberry ' seed oil, blueberry seed oil, raspberry seed oil, yuzu essential oil, turmeric essential oil, garlic essential oil, wolfberry seed oil, jasmine essential oil, ginger essential oil, myrrh essential oil, orange essential oil, organic extra virgin olive oil, clove essential oil, calamus essential oil, cassia essential oil, cinnamon essential oil, frankincense essential oil, rosemary essential oil, eucalyptus essential oil, flaxseed oil, lemon essential oil, iemongrass essential oil, xiang mao essential oil, gal an gal root essential oil, licorice extract, pomegranate seed oil, ravin tsara essential oil, bergamot essential
- the formulation comprises emu oil and at least one additional ingredient selected from the group consisting of German chamomile essential oil,ixie chamomile essential oil, Roman chamomile essential oil, coconut oil, macadamia oil, jojoba wax, lime essential oil, grapefruit essential oil, blackberry' seed oil, blueberry seed oil, raspberry' seed oil, yuzu essential oil, turmeric essential oil, garlic essential oil, wolfberry seed oil Jasmine essential oil, ginger essential oil, myrrh essential oil, orange essential oil, organic extra virgin olive oil, clove essential oil, calamus essential oil, cassia essential oil, cinnamon essential oil, frankincense essential oil, rosemary essential oil, eucalyptus essential oil, flaxseed oil, lemon essential oil, Iemongrass essential oil, xiang mao essential oil, galangai root essential oil, licorice extract, pomegranate seed oil, ravintsara essential oil, bergamot essential oil, cinnamon leaf essential oil, bupleurum
- the formulation of the invention may comprise at least one additional ingredient selected from the group consisting of an oil, a phospholipid, a ceramide, cholesterol, a fatty acid, a vitamin, a mineral, an amino acid, a hyaluronic acid, a fusogen, a biofermentation product of fruit, seaweed or other plants, a therapeutic agent (e.g., a drug approved by U S. FDA for use in humans), an exosome, a bioactive ingredient, dead sea salt, an organic pea protein, an organic brown rice protein, N-acetyl cysteine, or a combination of two or more of the foregoing,
- a therapeutic agent e.g., a drug approved by U S. FDA for use in humans
- the formulation may also comprise a biosilicate (e.g., Food-Grade Diatomaceous Earth (FGDE)) and/or another pharmaceutically acceptable matrix.
- FGDE Food-Grade Diatomaceous Earth
- biosilicates and pharmaceutically acceptable matrices provide release of a component(s) of the formulation for an extended period of time.
- the extended release may, e.g., be provided at least for 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 26 hours, 28 hours, 30 hours, 36 hours, 48 hours, 60 hours, 72 hours, 96 hours, 5 days, 6 days, 7 days, 8 days, 9 days, or 10 days.
- the extended release may be provided up to 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 w3 ⁇ 4eks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, or longer, after application of the formulation to an affected area.
- the individual fatty acids or oils in the formulations of the invention may, e.g., act. as a carrier for incorporation and/or delivery of other phospholipids, ceramides, cholesterol, essential and free fatty acids, additional oils, vitamins, minerals, bioactive ingredients, and additional therapeutic agents into and/or through cell membranes and/or (ii) as a therapeutic agent, e.g., to correct an impairment in a cell membrane composition and/or function and/or (iii) to stimulate expression of stem cell transcription factors Sox -2, Nanog, Oct4, Kif4, and c- Mye and/or (iv) downregulate expression of markers of inflammation such as CO.X2, NO, TNF-a, and INQ8, thromboxane B2, prostaglandin E2, Jeukotriene B4, IFNy, interleukin-1 (IL-1), IL-6, IL-8, IL-12, and PPARy (v) stimulate production of anti-inflammatory cytokines and/or (vi) stimulate
- the mixture may comprise only vegetable oils, only animal oils or a combination of vegetable oils and animal oils, with or without at least one additional ingredient(s).
- the formulation comprises a base composition comprising a mixture of fatty acids and at least one additional ingredient.
- the fatty acids for the compositions may be contained in oil(s) included in the formulations.
- the formulations of the invention do not contain any conventional therapeutic agents (i.e., therapeutic agents approved by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of the disease in humans) and only contains oils and/or other materials that are considered Generally Recognized as Safe (GRAS) by U.S,
- the formulations of the invention may contain conventional therapeutic agents (i.e., therapeutic agents approved by the U.S. Food and Daig Administration (U.S. FDA) for the treatment of the disease in humans).
- conventional therapeutic agents i.e., therapeutic agents approved by the U.S. Food and Daig Administration (U.S. FDA) for the treatment of the disease in humans.
- a formulation according to the invention includes a mixture of at least two ingredients listed in Table 1 or elsewhere in this application.
- the ingredients for inclusion in the mixture and the amounts are selected based on the desired indication and/or needs of a particular subject (e.g., a human in need of a treatment), based on the guidelines provided herein below, and the knowledge of a person of ordinary skill in the art. It is contemplated that a mixture of any two (or more) ingredients from Table 1 could be used in the formulations of the invention.
- a formulation comprises a mixture comprising, in % by volume, from about 3% to about 7% macadamia nut oil, from about 0.5% to about 1% coconut oil and from about 90% to about 99% emu oil.
- the formulation comprises, in % by volume, about 5% macadamia nut oil, about 0.7% coconut oil and about 95% emu oil.
- the mixture may improve cell membrane composition and function, and when admixed with other substances may impart and/or improve ability to incorporate into or penetrate past a cell membrane or a membrane of a cellular organelle.
- a formulation comprises a mixture comprising, in % by volume, from about 0.03% to about 0.07% macadamia nut oil, from about 0.005% to about 0.009% coconut oil and from about 90% to about 99% Emu oil.
- the formulation comprises, in % by volume, about 0.05% macadamia nut oil, about 0.007% coconut oil and about 99% emu oil.
- the mixture may improve cel! membrane composition and function, and when admixed with other substances may impart and/or improve the formulation’s ability to incorporate into or penetrate past a cell membrane or a membrane of a cellular organelle,
- a formulation comprises a mixture comprising, in % by volume, from about 3% to about 7% macadamia nut oil, from about 0.5% to about 1% coconut oil and from about 90% to about 99% high oleic sunflower seed oil.
- the formulation comprises, in % by volume, about 5% macadamia nut oil, about 0.7% coconut oil and about 95% high oleic sunflower seed oil.
- the mixture may improve cell membrane composition and function, and when admixed with other substances may impart and/or improve the formulation’s ability to incorporate into or penetrate past a cell membrane or a membrane of a cellular organelle,
- a formulation comprises a mixture comprising, in % by volume, from about 0.03% to about 0.07% macadamia nut oil, from about 0.005% to about 0.009% coconut oil and from about 90% to about. 99% high oleic sunflower seed oil.
- the formulation comprises, in % by volume, about 0.05% macadamia nut oil, about 0.007% coconut oil and about 99% high oleic sunflower seed oil.
- the mixture may improve cell membrane composition and function, and when admixed with other substances may impart and/or improve the formulation’s ability to incorporate into or penetrate past a cell membrane or a membrane of a cellular organelle.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 70% to 85% olive oil, from about 2% to about 7% essential oil of clove, from about 2% to about 7% cinnamon essential oil, from about 2% to about 7% rosemary essential oil, from about 2% to about 7% eucalyptus essential oil, from about 2% to about 7% lemon essential oil, from about 0.05% to about 4% ravintsara essential oil, and from about 0.05% to about 3% cinnamon leaf essential oil.
- the mixture may exhibit, e.g., antimicrobial, antiviral and antifungal properties as well as wound healing properties.
- a formulation comprises a mixture comprising, in % by volume, from about 0.03% to about 0,07% macadamia nut oil, from about 0,005% to about 0.009% coconut oil, from about 2% to about 7% essential oil of clove, from about 2% to about 7% cinnamon essential oil, from about 2% to about 7% rosemary? essential oil, from about 2% to about 7% eucalyptus essential oil, from about 2% to about 7% lemon essential oil, from about 0.05% to about 4% ravintsara essential oil, from about 0.05% to about 3% cinnamon leaf essential oil, and from about 50% to about 95% high oleic sunflower seed oil.
- the mixture may exhibit, e.g., antimicrobial, antiviral and antifungal properties as well as wound healing properties.
- a formulation comprises a mixture comprising, in % by volume, from about 0.03% to about 0.07% macadamia nut oil, from about 0.005% to about 0.009% coconut oil, from about 2% to about 7% essential oil of clove, from about 2% to about 7% cinnamon essential oil, from about 2% to about 7% rosemary essential oil, from about 2% to about 7% eucalyptus essential oil, from about 2% to about 7% lemon essential oil, from about 0.05% to about 7% ravintsara essential oil, from about 0.05% to about 7% cinnamon leaf essential oil, from about 0,05% to about 10% frankincense essential oil, from about 0.05% to about 10% myrrh essential oil, and from about 50% to about 95% high oleic sunflower seed oil.
- the mixture may exhibit, e.g., antimicrobial, antiviral and antifungal properties as well as wound healing properties.
- a formulation comprises a mixture comprising, in % by volume, from about 0.03% to about 0.07% macadamia nut oil, from about 0.005% to about 0.009% coconut oil, from about 2% to about 7% essential oil of clove, from about 2% to about 7% cinnamon essential oil, from about 2% to about 7% rosemary essential oil, from about 2% to about 7% eucalyptus essential oil, from about 2% to about 7% lemon essential oil, from about 0.05% to about 7% ravintsara essential oil, from about 0.05% to about 7% ravensara essential oil, from about 0.05% to about 7% laurel leaf, from about 0.05% to about 7% cinnamon leaf essential oil, from about 0.05% to about 7% rosalina essential oil, from about 0.05% to about 7% niaouli essential oil, from about 0.05% to about 7% frankincense essential oil, from about 0.05% to about 7% myrrh essential oil, from about 0.05% to about 7% myr
- the mixture may exhibit, e.g., antimicrobial, antiviral and antifungal properties, may exhibit wound-healing properties, and may relieve a bronchospasm, a runny nose, cough, and/or discomfort and/or irritation from wearing a mask,
- a formulation comprises a mixture comprising, in % by volume, from about 0.03% to about 0.07% macadamia nut oil, from about 0.005% to about 0.009% coconut oil, from about 2% to about 7% essential oil of clove, from about 2% to about 7% cinnamon essential oil, from about 2% to about 7% rosemary essential oil, from about 2% to about 7% eucalyptus essential oil, from about 2% to about 7% lemon essential oil, from about 0.05% to about 7% ravintsara essential oil, from about 0.05% to about 7% cinnamon leaf essential oil, from about 0.05% to about 7% frankincense essential oil, from about 0.05% to about 7% myrrh essential oil, from about 1% to about 17% white thyme essential oil, and from about 50% to about 95% high oleic sunflower seed oil.
- the mixture may exhibit, e.g., antimicrobial, antiviral and antifungal properties.
- a formulation comprises a mixture comprising, in % by volume, from about 0,2% to about 0.7% macadamia nut oil, from about 0.1% to about 0.5% coconut oil, from about 1% to about 7% essential oil of clove, from about 1% to about 7% cinnamon essential oil, from about 1% to about 7% rosemary essentia! oil, from about.
- the mixture may exhibit, e.g., antimicrobial, antiviral and antifungal properties as well as wound healing properties.
- a formulation comprises a mixture comprising, in % by volume, from about 0.1% to about 5% macadamia nut oil, from about 0.05% to about 2% coconut oil, from about 2% to about 7% essential oil of clove, from about 2% to about 7% cinnamon essential oil, from about 2% to about 7% rosemary essential oil, from about 2% to about 7% eucalyptus essential oil, from about 2% to about 7% lemon essential oil, from about 0.05% to about 7% ravintsara essential oil, from about 0.01% to about 7% cinnamon leaf essential oil, from about 0.01% to about 7% frankincense essential oil, from about 0.01% to about 7% myrrh essential oil, from about 1% to about 17% white thyme essential oil, from about 1% to about 17% xiang mao essential oil, from about 1% to about 17% cymbopogon citratus (lemongrass) essential oil, and from about 30% to about 95% high ole
- a formulation comprises a mixture comprising, in % by volume, from about 0,1% to about 5% macadamia nut oil, from about 0.01% to about 2% coconut oil, from about 2% to about 7% essential oil of clove, from about 2% to about 7% cinnamon essential oil, from about 2% to about 7% rosemary essential oil, from about 2% to about 7% eucalyptus essential oil, from about 2% to about 7% lemon essential oil, from about 0.05% to about 7% ravintsara essential oil, from about 0.01% to about 7% cinnamon leaf essential oil, from about 0.01% to about 7% frankincense essential oil, from about 0.01% to about 7% myrrh essential oil, from about 1% to about 17% white thyme essential oil, from about 1% to about 17% xiang mao essential oil, from about 1% to about 17% cymbopogon citratus (lemongrass) essential oil, from about 1% to about 17% coriander seed
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 65% to 85% olive oil, from about 2% to about 7% essentia! oil of grapefruit, 2% to about 7% essential oil of clove, from about 2% to about 7% cinnamon essential oil, from about 2% to about 7% rosemary essential oil, from about 2% to about 7% eucalyptus essential oil, from about 2% to about 7% lemon essential oil, from about 0.05% to about 4% ravintsara essential oil, from about 0.01% to about 3% cinnamon leaf essential oil, and from about 0.01% to about 3% frankincense essential oil.
- the mixture may exhibit, e.g., antimicrobial, antiviral and antifungal properties, wound-healing properties, and facilitate recovery' from a microbial, viral or a fungal infection.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 0.2% to about 0/7% macadam ia nut oil, from about 0.1% to about 0.5% coconut oil, from about 50% to 95% high oleic acid sunflower seed oil, from about 1% to about 12% essential oil of grapefruit, 1% to about 7% essential oil of clove, from about 1% to about 7% cinnamon essential oil, from about 1% to about 7% rosemary' essential oil, from about 1% to about 12% eucalyptus essential oil, from about 1% to about 12% lemon essential oil, from about 1% to about 12% frankincense essential oil, from about 1% to about 12% myrrh essential oil, and from about 1% to about 12% xiang mao essential oil, from about 1% to about 12% essential oil of rosalina, 1% to about 12% essential oil of palmarosa, from about 1% to about 12% essential oil of ravintsara, from about
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 20% to 50% olive oil, from about 40% to 55% high oleic acid sunflower seed oil, from about 0.001% to about 3% coconut oil, from about 0.01% to about 5% essential oil of macadamia nut oil, from about 1% to about 7% clove essential oil, from about 1% to about 7% cinnamon essential oil, from about 1% to about 7% rosemary essential oil, from about 1% to about 7% eucalyptus essential oil, from about 1% to about 7% lemon essential oil, from about 0.01% to about 3% ravintsara essential oil, and from about 0.001% to about 2% cinnamon leaf essential oil, from about 0.01% to about 7% essential oil of frankincense, 0.01% to about 7% essential oil of white thyme, from about 0.01% to about 7% rosalina essential oil, from about 0.01% to about 7% palmarosa essential oil, from about 0.001% to about 7% palma
- the mixture may exhibit, e.g., antimicrobial, antiviral, antifungal properties, anti-trypanosomal properties, wound-healing properties, and facilitate recovery from a microbial, viral, a fungal or trypanosomal infection.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 20% to 50% olive oil, from about 40% to 55% high oleic acid sunflower seed oil, from about 0.001% to about 3% coconut oil, from about 0.01% to about 5% essential oil of macadamia nut oil, from about 1% to about 7% clove essential oil, from about 1% to about 7% cinnamon essential oil, from about 1% to about 7% rosemary essential oil, from about 1% to about 7% eucalyptus essential oil, from about 1% to about 7% lemon essential oil, from about 0.01% to about 1% ravintsara essential oil, and from about 0.001% to about 7% cinnamon leaf essential oil, from about 0.01% to about 7% essentia!
- oil of frankincense from about 0.01% to about 7% essential oil of myrrh, 0.01% to about 7% essentia! oil of white thyme, from about 0.01% to about 7% rosalina essentia! oil, from about 0.01% to about 7% palmarosa essential oil, from about 0,01% to about 7% niaouli essential oil, from about 0.01% to about 7% laurel leaf essential oil, from about 0.01% to about 7% litsea essential oil, from about 0.01% to about 7% essential oil of xiang mao, from about 0.01% to about 7% essential oil of cymhopogon citratus, from about 0.01% to about 7% essential oil of coriander seed.
- the mixture may exhibit, e.g., antimicrobial, antiviral, antifungal properties, antiparasitic and wound-healing properties, and facilitate recovery from a microbial, viral, a fungal or a parasitic infection.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 40% to 65% high oleic acid sunflower seed oil, from about 0.001% to about 3% coconut oil, from about 0.01% to about 7% of macadamia nut oil, from about 1% to about 10% clove oil, from about 1% to about 10% cinnamon essential oil, from about 1% to about 10% rosemary essential oil, from about 1% to about 10% eucalyptus essential oil, from about 1% to about 10% lemon essential oil, from about 1% to about 10% ravintsara essential oil, and from about 10% to about 10% cinnamon leaf essential oil, from about 1% to about 10% essential oil of frankincense, 1% to about 10% essential oil of myrrh, from about 1% to about 10% white thyme essential oil, from about 0,01% to about 10% rosalina essential oil, from about 1% to about 10% xiang mao essential oil, from about 1% to about 10% cymbopogon mart
- the mixture may exhibit, e.g., antimicrobial, antiviral, antifungal properties, antiparasitic and wound-healing properties, and facilitate recovery from a microbial, viral, a fungal or a parasitic infection.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 6% German chamomile essential oil, from about 94% to about 98% emu oil.
- the mixture may alleviate pain and inflammation.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 5% German chamomile essential oil, from about 0.01% to about 1% peppermint essential oil, from about 0.01% to about 1% Bridal Garden Jerusalem anointing oil (by www.thenewjerusalem.co), and from about 80%-90% emu oil.
- the mixture may alleviate pain and inflammation.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 1% to about 25% biosilicates loaded with minerals, amino acids, vitamins and other ingredients (e.g., bioactive compounds) for long- acting relief of pain and anxiety, delivery of substances required for tissue repair, from about 0.01% to about 2% German chamomile essential oil, about 0,01% to about 3%ixie chamomile essential oil, from about 0.01% to about 2% Roman chamomile essential oil, from about 0.01% to about 2% jasmine essential oil, from about 0.01% to about 2% lemongrass essential oil, from about 70% to about 99% emu oil.
- the mixture may alleviate pain and inflammation.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 15% to about 25% biosilicates loaded with minerals, amino acids, vitamins and other bioactive compounds for long-acting relief of pain and anxiety, delivery of substances required for tissue repair, about 10% to about 15%sammlung chamomile essential oil, from about 2% to about 15% Roman chamomile essential oil, from about 6% to about 9% jasmine essential oil, from about 6% to about 9% vanilla p!anifolia essential oil, from about 50% to about 99% emu oil.
- the mixture may alleviate pain and inflammation.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 1% to about 25% biosilicates loaded with minerals, amino acids, vitamins and other bioactive compounds for long-acting relief of pain and anxiety, delivery of substances required for tissue repair, from about 0.01% to about 30% German chamomile essential oil, about 0.01% to about 30%ixie chamomile essential oil, from about 0.01% to about 30% Roman chamomile essential oil, from about 0.01% to about 2% jasmine essential oil, from about 0.01% to about 2% lemongrass essential oil, from about 2%-4% coconut oil, from about 25-29% macadamia nut oil, from about 20% to about 70% emu oil.
- the mixture may alleviate pain and inflammation.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 1% to about 25% biosiiieates loaded with minerals, amino acids, vitamins and other bioactive compounds for long-acting relief of pain and anxiety, delivery of substances required for tissue repair, from about 0.01% to about 30% German chamomile essential oil, about 0.01% to about 30% mecanic chamomile essential oil, from about 0.01% to about 30% Roman chamomile essential oil, about 0.01% to about 3% frankincense essential oil, from about 0.01% to about 3% myrrh essential oil, from about 2% to about 5% of macadamia nut oil, from about 0.01% to about 2% of coconut oil, from about 1% to about 4% jasmine essential oil, from about 1% to about 4% lemongrass essential oil, from about 25% to about 85% emu oil.
- the mixture may exhibit alleviate pain and inflammation.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 5% to about 18% biosilicates loaded with minerals, amino acids, vitamins and other bioactive compounds for long-acting relief of pain and anxiety, delivery of substances required for tissue repair, from about 0.01% to about 3% German chamomile essential oil, about 0.01% to about 3% mecanic chamomile essential oil, from about 0.01% to about 3% Roman chamomile, from about 1% to about 8% frankincense oil, from about 1% to about 8% myrrh oil, from about 2% to about 27% of macadamia nut oil, from about 0.01% to about 10% of coconut oil, from about 0.01% to about 3% jasmine essential oil, from about 0.01% to about 3% lemongrass essential oil, from about 35% to about 85% emu oil.
- the mixture may alleviate pain and inflammation.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 25% biosilicates loaded with minerals, amino acids, vitamins and other bioactive compounds for long-acting relief of pain and anxiety, delivery of substances required for tissue repair, from about 0.01% to about 30% German chamomile essential oil, about 0.01% to about 30% mecanic chamomile essential oil, from about 0.01% to about 30% Roman chamomile essential oil, from about 0.01% to about 10% frankincense essential oil, from about 0.01% to about 10% myrrh essential oil, from about 0.01 % to about 2% of jasmine essential oil, from about 0.01% to about 2% of lemongrass essential oil, from about 0.01% to about 3% sweet orange essential oil, from about 0.01% to about 3% bitter orange essential oil, from about 0.01% to about 3% rosemary' essential oil, from about 0.01% to about 3% galangal essential oil, from about 0.01% to about 3% xiang ma
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 25% biosilicates loaded with minerals, amino acids, vitamins and other bioactive compounds for long-acting delivery of substances required for tissue repair, from about 0.01% to about 3% gallic acid, from about 0.01% to about 30% German chamomile essential oil, about 0.01% to about 30% mecanic chamomile essential oil, from about 0.01% to about 30% Roman chamomile essential oil, from about 0.01% to about 10% frankincense essential oil, from about 0.01% to about 10% myrrh essential oil, from about 0.01% to about 2% of jasmine essential oil, from about 0.01% to about 2% of lemongrass essential oil, from about 0.01% to about 2% of cinnamon essential oil, from about 0.01% to about 2% of cinnamon leaf essential oil, from about 0.01% to about 2% of rosemary' essential oil, from about 0.01% to about 3% sweet orange essential oil, from about 0.01% to
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 25% biosilicates loaded with minerals, amino acids, vitamins and other bioactive compounds for long-acting delivery of substances required for tissue repair, from about 0.01% to about 3% gallic acid, from about 0.01% to about 30% German chamomile essential oil, about 0.01% to about 30% provoke chamomile essentia!
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 25% biosilicates loaded with minerals, amino acids, vitamins and other bioactive compounds for long-acting delivery' of substances required for tissue repair, from about 0.01% to about 3% gallic acid, from about 0.01% to about 30% German chamomile essential oil, about 0.01% to about 30% mecanic chamomile essential oil, from about 0.01% to about 30% Roman chamomile essential oil, from about 0.01% to about 10% frankincense essential oil, from about 0.01% to about 10% myrrh essential oil, from about 0.01% to about 2% of jasmine essential oil, from about 0,01% to about 2% of lemongrass essential oil, from about 0.01% to about 2% of cinnamon essential oil, from about 0.01% to about 2% of cinnamon leaf essential oil, from about 0.01% to about 2% of rosemary' essential oil, from about 0.01% to about 3% sweet orange essential oil, from about 0.01%
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 10% biosilicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds for long-acting delivery of substances required for tissue repair.
- the formulation may comprise from about 0.01% to about 7% ubiquinol (final concentration of about 30 - 50 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 300 - 350 mcg/ml), from about 0.01% to about 10% vitamin D (final concentration of about 690 - 730 lU/ml), from about 0.01% to about 10% vitamin E (final concentration of about 5 - 15 mg/mi of d-alpha tocopherol, final concentration of mixed tocopherol s, including d-beta, d-gamma, and d-delta tocopherol is from about 0.001 to 1 mg/ml), from about 0.01% to about 10% vitamin K2 MK7 (final concentration of about 10 - 40 mcg/ml), about 0.01% to about 25% vitamin C, from about 0.01% to about 4% alpha arhutin, from about 0.01% to about 3% gallic acid, from about.
- 0.01% to about 10% frankincense essentia! oil from about. 0.01% to about 10% myrrh essential oil, from about 0.01% to about 5% kojic acid, from about 0.01% to about 10% licorice root extract, from about 0,01% to about 12% of niacinamide, from about 0,01% to about 6% of kaempferia galanga essential oil, from about 0.01% to about 5% niaouli essential oil, from about 0.01% to about 3% glutathione, from about 0.01% to about 12% hyaluronic acid, from about 0.01% to about 5% clove essential oil, from about 0.01% to about 5% eucalyptus essential oil, from about 0.01% to about 5% lemon essential oil, from about 0.01% to about 5% rosemary' essential oil, from about 0.01% to about 5% cinnamon essential oil, from about 0.01% to about 5% cinnamon leaf essentia!
- the mixture may have skin whitening and age spot fading properties.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 10% biosiiicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery of substances required for tissue repair.
- the formulation may, e.g., comprise from about 0.01% to about 7% ubiquinoi (final concentration of about 30 - 50 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 300 - 350 mcg/m!), from about 0.01% to about 10% vitamin D (final concentration of about 690 - 730 IlJ/ml), from about 0.01% to about 10% vitamin E (final concentration of about 5 - 15 mg/m!
- d-alpha tocopherol final concentration of mixed tocopherois, including d-beta, d-gamma, and d-delta tocopherol is from about 0.001 to 1 mg/ml), from about 0.01% to about 10% vitamin K2 MK7 (final concentration of about 10 - 40 mcg/ml), about 0.01% to about 25% vitamin C, from about 0.01% to about 3% gallic acid, from about 0.01% to about 3% saturated dead sea salt solution, from about 0.01% to about 3% glutathione, from about 0.01% to about 12% hyaluronic acid, from about 0.01% to about 10% licorice root extract, from about 0.05% to about 12% of niacinamide, from about 0.001% to about 1% of ginger essentia!
- frankincense essential oil from about. 0.01% to about 10% frankincense essential oil, from about 0.01% to about 10% myrrh essentia! oil, from about 0.01% to about 6% essential oil of kaempferia galanga, from about 0.01% to about 3% palrnarosa essential oil, from about 0.01% to about 5% clove essential oil, from about 0.01% to about 5% eucalyptus essential oil, from about 0.01% to about 5% lemon essential oil, from about 0.01% to about 5% rosemary?
- the mixture may have anti-acne properties. It may also improve skin texture.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 10% biosilicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery of substances required for tissue repair.
- the formulation may comprise from about 0.01% to about 7% ubiquinol (final concentration of about 30 - 50 mg/ml), from about 0.01% to about 3% retinol, from about 0.01% to about 4% vitamin A (final concentration of about 300 - 350 mcg/ml), from about 0.01% to about 10% vitamin D (final concentration of about 690 - 730 IlJ/m!), from about 0.01% to about 10% vitamin E (final concentration of about 5 - 15 mg/m!
- d-a!pha tocopherol final concentration of mixed tocopherols, including d-beta, d-gamma, and d-delta tocopherol is from about 0,001 to 1 mg/ml), from about 0.01% to about 10% vitamin K2 MK7 (final concentration of about 10 - 40 mcg/ml), about 0.01% to about 25% vitamin C, from about 0.01% to about 3% gallic acid, from about 0.01% to about 3% saturated dead sea salt solution, from about 0.01% to about 3% glutathione, from about 0.01% to about 12% hyaluronic acid, from about 0.01% to about 10% licorice root extract, from about 0.05% to about 12% of niacinamide, from about 0.001% to about 1% of ginger essential oil, from about 0.01% to about 15% frankincense essential oil, from about 0.01% to about 15% myrrh essential oil, from about 0.01% to about 6% essential oil of kaempferia ga!
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 30% biosilicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery of substances required for tissue repair.
- the formulation may comprise from about 0.01% to about 7% ubiquinol (final concentration of about 1 - 1000 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 300 - 350 mcg/ml), from about 0.01% to about 10% vitamin D (final concentration of about 690 - 730 TU/ml), from about 0.01% to about 10% vitamin E (final concentration of about 5 — 15 mg/ml of d-alpha tocopherol, final concentration of mixed tocopherol s, including d-beta, d-gamma, and d-delta tocopherol is from about 0.001 to 1 mg/ml), from about 0.01% to about 10% vitamin K2 MK7 (final concentration of about 10 - 40 mcg/ml), from about 0.001% to about 10% saturated dead sea salt solution, from about 0.01% to about 12% hyaluronic acid, from about 0.01% to about 12% vegetable glycerin, from about 0.01%
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 30% biosilicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery of substances required for tissue repair.
- the formulation may comprise from about 0.01% to about 7% ubiquinol (final concentration of about 30 - 1000 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 5700 - 6500 mcg/ml), from about 0.01% to about 10% vitamin D (final concentration of about 3000 - 4000 lU/ml), from about 0.01% to about 10% vitamin E (final concentration of about 25 - 35 mg/ml of d-alpha tocopherol, final concentration of mixed tocopherol s, including d-beta, d-gamma, and d-delta tocopherol is from about 0.001 to about 1 mg/ml), from about 0.01% to about 10% vitamin K2 MK7 (final concentration of about 50 - 100 mcg/ml), from about 0.001% to about 10% saturated dead sea salt solution, from about 0.01% to about 20'% hyaluronic acid, from about 0.01% to about 20% vegetable glycerin, from
- the mixture may be particularly useful for treatment of eczema, psoriasis, unspecified rashes and wounds of the skin.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 30% biosilicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery of substances required for tissue repair.
- the formulation may comprise, e.g., from about 0.01% to about 7% ubiquinol (final concentration of about 30 - 1000 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 5700 - 6500 mcg/ml), from about 0.01% to about 10% vitamin D (final concentration of about 3000 - 4000 HJ/m!
- vitamin E final concentration of about 25 - 35 mg/ml of d-alpha tocopherol, final concentration of mixed tocopherol s, including d-beta, d-gamma, and d-delta tocopherol is from about 0.001 to about 1 mgfinl
- vitamin K2 MK7 final concentration of about 50 - 100 mcg/ml
- 0.001% to about 10% saturated dead sea salt solution from about 0.01% to about 20% hyaluronic acid, from about 0.01% to about 20% vegetable glycerin, from about 0.01% to about 6% German chamomile essential oil, from about 0.01% to about 20%Institut chamomile essential oil, from about 0.01% to about 6% Roman chamomile essentia!
- the mixture may be particularly useful for treatment of eczema, psoriasis, unspecified rashes and wounds of the skin: and may reduce biological causes of itching.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 30% biosiiicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery of substances required for tissue repair.
- the formulation may, e.g., comprise from about 0.01% to about 7% ubiquinol (final concentration of about 30 - 1000 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 5700 - 6500 mcg/ml), from about 0.01% to about 10% vitamin D (final concentration of about 3000 - 4000 IU/ml), from about 0.01% to about 10% vitamin E (final concentration of about 25 - 35 mg/ml of d ⁇ alpha tocopherol, final concentration of mixed tocophero!s, including d-beta, d-gamma, and d-delta tocopherol is from about 0.001 to about 1 mg/ml), from about 0.01% to about 10% vitamin K2 MK7 (final concentration of about 50 - 100 mcg/ml), about 0.01% to about 25% vitamin C, from about 0.01% to about 4% alpha arhutin, from about 0.01% to about 5% kojic acid, from about 0.0
- 5% palmarosa essentia! oil from about 0.01% to about 3% glutathione, from about 0.001% to about 10% saturated dead sea salt solution, from about 0.01% to about 20% hyaluronic acid, from about 0.01% to about 20% vegetable glycerin, from about 0.01% to about 6% German chamomile essential oil, from about 0.01% to about 10% mecanic chamomile essential oil, from about 0.01% to about 6% Roman chamomile essential oil, from about 0.01% to about 3% jasmine essential oil, from about 0.01% to about 3% lemongrass essential oil, from about 0.01% to about 5% lemon essential oil, from about 0.01% to about 5% eucalyptus essential oil, from about 0.01% to about 5% rosemary essentia!
- cinnamon essential oil from about 0.01% to about 5% clove essential oil, from about 0.01% to about 5% cinnamon essential oil, from about 0.01% to about 5% cinnamon leaf essential oil, from about 0.01% to about 5% ravintsara essential oil, from about 0.01% to about 20% frankincense essential oil, from about 0.01% to about 20% myrrh essential oil, from about 0.01% to about 20% lecithin, from about 0.001% to about 5% gallic acid, from about 0.001% to about 5% turmeric essential oil, from about 5%-2Q% of sea kelp bioferment (extract of fermented seaweed), from about 0.01% to about 30% macadamia nut oil, from about 0.01% to about 5% coconut oil, from about 15% to about 90% emu oil.
- sea kelp bioferment extract of fermented seaweed
- the mixture may be particularly useful for treatment of eczema, psoriasis and unspecified rashes and skin wounds.
- the mixture is formulated to result in anti-aging, skin- brightening, and cosmetic moisturizing properties.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 30% biosilicat.es loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery of substances required for tissue repair.
- the formulation may comprise, e.g., from about 0.01% to about 1% retinol, from about 0.01% to about 7% ubiquinol (final concentration of about 30 - 1000 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 5700 - 6500 mcg/mi), from about 0.01% to about 10% vitamin D (final concentration of about 3000 - 4000 lU/ml), from about 0.01% to about 10% vitamin E (final concentration of about. 25 - 35 mg/m!
- d-a!pha tocopherol final concentration of mixed tocopherols, including d-beta, d-gamma, and d-de!ta tocopherol is from about 0,001 to about 1 mg/ml), from about 0.01% to about 10% vitamin K2 MK7 (final concentration of about 50 - 100 mcg/ml), about 0.01% to about 25% vitamin C, from about 0.01% to about 4% alpha arbutin, from about 0.01% to about 5% kojic acid, from about 0.01% to about 10% licorice root extract, from about 0.01% to about 10% ginger root extract, from about 0.01% to about 10% ginger root essential oil, from about 0.01% to about 12% of niacinamide, from about 0.01% to about 6% of essential oil of kaempferia galanga, from about 0.01% to about.
- 5% niaoufi essential oil from about 0.01% to about 5% palmarosa essential oil, from about 0.01% to about 3% glutathione, from about 0.001% to about 10% saturated dead sea salt solution, from about 0.01% to about 20% hyaluronic acid, from about 0.01% to about 20% vegetable glycerin, from about 0,01% to about 6% German chamomile essential oil, from about 0.01% to about 10% mecanic chamomile essential oil, from about 0.01% to about 6% Roman chamomile essential oil, from about 0.01% to about 3% jasmine essential oil, from about 0.01% to about 3% lemongrass essential oil, from about 0.01% to about 5% lemon essential oil, from about 0.01% to about 5% eucalyptus essential oil, from about.
- rosemary essentia! oil from about. 0.01% to about 5% clove essential oil, from about 0.01% to about 5% cinnamon essential oil, from about 0.01% to about 5% cinnamon leaf essential oil, from about 0.01% to about 5% ravintsara essential oil, from about 0.01% to about 20% frankincense essential oil, from about 0.01% to about 20% myrrh essential oil, from about 0.01% to about 20% lecithin, from about 0.001% to about 5% gallic acid, from about 0.001% to about 5% turmeric essential oil, from about 5%-2Q% of sea kelp bioferment (extract of fermented seaweed), from about 0.01% to about 30% macadamia nut oil, from about 0.01% to about 5% coconut oil, from about 15% to about 90% emu oil.
- clove essential oil from about 0.01% to about 5% cinnamon essential oil, from about 0.01% to about 5% cinnamon leaf essential oil, from about 0.01% to about 5% ravintsara essential oil, from about
- the mixture may be particularly useful for treatment of eczema, psoriasis and unspecified rashes and wounds of the skin.
- the mixture is formulated to result in anti-aging, skin-brightening, and cosmetic moisturizing properties.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 70% biosilicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery' of substances required for tissue repair.
- the formulation may comprise from about 0.01% to about 1% retinol, from about 0.01% to about 7% ubiquinol (final concentration of about 30 - 1000 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 5700 - 6500 mcg/ml), from about 0.01% to about 10% vitamin D (final concentration of about 3000 - 4000 IU/mi), from about 0.01% to about 10% vitamin E (final concentration of about 25 - 35 mg/ml of d- alpha tocopherol, final concentration of mixed tocopherols, including d-beta, d-gamma, and d- delta tocopherol is from about 0.001 to about 1 mg/ml), from about 0.01% to about 10% vitamin K2 MK7 (final concentration of about 50 - 100 mcg/ml), about 0.01% to about 25% vitamin C, from about 0.01% to about 4% alpha arbutin, from about 0.01% to about 5% k
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 30% biosilicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery ' of substances required for tissue repair.
- the formulation may comprise from about 0.01% to about 7% ubiquinol (final concentration of about 30 - 1000 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 5700 - 6500 mcg/ml), from about 0.01% to about 10% vitamin D (final concentration of about 3000 - 4000 lU/m!), from about 0.01% to about 10% vitamin E (final concentration of about 25 - 35 mg/ml of d-alpha tocopherol, final concentration of mixed tocopherol s, including d-beta, d-gamma, and d-delta tocopherol is from about 0.001 to about 1 mg/ml), from about 0.01% to about 10% vitamin K2 MK7 (final concentration of about 50 - 100 mcg/ml), about 0.01% to about 5% vitamin C, from about 0.01% to about 10% of niacinamide, from about 0.01% to about 3% glutathione, from about 0.001% to about
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 30% biosilicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery of substances required for tissue repair.
- the formulation may, e.g., comprise from about 0.01% to about 7% ubiquinol (final concentration of about 30 - 1000 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 5700 - 6500 mcg/ml), from about 0.01% to about 10% vitamin D (final concentration of about 3000 - 4000 IU/ml), from about 0.01% to about 10% vitamin E (final concentration of about 25 - 35 mg/ml of d ⁇ alpha tocopherol, final concentration of mixed tocopherols, including d-beta, d-gamma, and d-de!ta tocopherol is from about 0.001 to about 1 mg/ ' ml), from about 0.01% to about 10% vitamin K2 MK7 (final concentration of about 50 - 100 mcg/ml), about 0.01% to about 25% vitamin C, from about 0.01% to about 1% licorice root extract, from about 0.01% to about 1% ginger root extract, from
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 30% biosiiicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery of substances required for tissue repair.
- the formulation may, e.g., comprise from about 0.01% to about 7% ubiquinol (final concentration of about 30 - 1000 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 5700 - 6500 mcg/ml), from about 0.01% to about 10% vitamin D (final concentration of about 3000 - 4000 flj/ml), from about 0.01% to about 10% vitamin E (final concentration of about 25 - 35 mg/ml of d-alpha tocopherol, final concentration of mixed tocopherol s, including d-beta, d-gamma, and d-delta tocopherol is from about 0.001 to about 1 mg/ml), from about 0.01% to about 10% vitamin K2 MK7 (final concentration of about 50 - 100 mcg/ml), about 0.01% to about 25% vitamin C, from about 0.01% to about 1% licorice root extract, from about 0.01% to about 1% ginger root extract, from about
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 30% biosilicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery' of substances required for tissue repair.
- the formulation may, e.g., comprise from about 0.01% to about 3% alpha lipoic acid (final concentration of about 100 to about 1000mg/ml), from about 0.01% to about 3% calcium (final concentration of about 100 to about 1000mg/ml), from about 0.01% to about 7% ubiquinol (final concentration of about 30 - 1000 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 5700 - 6500 mcg/m!), from about 0.01% to about 10% vitamin D (final concentration of about 3000 - 4000 lU/ml), from about 0.01% to about 10% vitamin E (final concentration of about 25 - 35 mg/ml of d-alpha tocopherol, final concentration of mixed tocopherol s, including d-beta, d-gamma, and d-delta tocopherol is from about 0.001 to about 1 mg/ml), from about 0.01% to about 10% vitamin K2 Y!K7 (final concentration
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 30% biosilicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery of substances required for tissue repair.
- the formulation may comprise, e.g., from about 0.01% to about 7% ubiquinol (final concentration of about 30 - 1000 mg/ml), from about 0.01% to about 5% vitamin A (final concentration of about 5700 - 10,000 mcg/ml), from about 0.01% to about 10% vitamin D (final concentration of about 3000 - 8,000 iU/ml ), from about 0.01% to about 10% vitamin E (final concentration of about 25 - 500 mg/ml of d-a!pha tocopherol, final concentration of mixed tocopherol s, including d-beta, d-gamma, and d-delta tocopherol is from about 0,001 to about 3 mg/ml), from about 0.01% to about 10% vitamin K2 MK7 (final concentration of about 50 - 1000 mcg/ml), about 0.01% to about 25% vitamin C, from about 0.01% to about 1% licorice root extract, from about 0.01% to about 1% ginger root extract, from about 1%
- a nut oil from about 0.01% to about 5% coconut oil, from about 15% to about 90% emu oil. These formulations are particularly useful for wound healing, especially to improve appearance of keloid and scar tissue. They are intended to be applied on the intact keloid or scar tissue.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 15% to about 25% biosilicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds for long-acting relief of pain, and delivery of substances required, e.g., for tissue repair.
- the formulation may comprise, about 10% to about 30%ixie chamomile essential oil, from about 2% to about 30% Roman chamomile essential oil, from about 0.01% to about 3% of German chamomile essential oil, from about 6% to about 9% jasmine essentia!
- the invention is directed to a formulation that, is half the strength as listed. These formulations may be particularly useful in treating leukoplakia and tongue lesions,
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 30% biosilicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery of substances required for tissue repair.
- the formulation may comprise from about 0.01% to about 0.05% ubiquinol (final concentration of about 1 - 5 mg/ml), from about 0.01% to about 0.05% vitamin A (final concentration of about 50 - 100 mcg/mi), from about 0.01% to about 0.05% vitamin D (final concentration of about 100 - 400 lU/ml), from about 0.01% to about 0.05% vitamin E (final concentration of about 5 - 15 mg/ml of d-alpha tocopherol, final concentration of mixed tocopherols, including d-beta, d-gamma, and d-delta tocopherol is from about 0.001 to about 1 mg/ml), from about 0.01% to about 0.05% vitamin K2 MK7 (final concentration of about 20 - 50 rncg/ml), about 0.01% to about 30%sammlung chamomile essential oil, from about 0.01% to about 30% Roman chamomile essentia!
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 30% biosilicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery ' of substances required for tissue repair.
- the formulation may comprise from about 0.01% to about 20%
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 0.01% to about 2% Neue chamomile essential oil, from about 1% to about 3% coconut oil, from about 4% to about 7% macadamia nut oil, from about 1% to about 3% vegetable glycerin, from about 0.01% - 5% melatonin (for a final concentration of about 100 to about 160 meg/ spray), and from about 80% to about 99% emu oil.
- These formulations may be particularly useful for treating jetlag, insomnia, and may be administered as a nasal spray for targeted delivery to vasculature nearest the brain (e.g., one spray per nostril 30 minutes before desired bedtime).
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 2% to about 30% biosilicat.es loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery of substances required for tissue repair.
- the formulation may comprise, e.g., from about 0.01% to about 7% ubiquinol (final concentration of about 30 - 1000 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 5700 - 6500 mcg/ml), from about 0.01% to about 10% vitamin D (final concentration of about 3000 - 4000 IU/mJ), from about 0.01% to about 10% vitamin E (final concentration of about. 25 - 35 mg/m!
- d-a!pha tocopherol final concentration of mixed tocopherols, including d-beta, d-gamma, and d-de!ta tocopherol is from about 0.001 to about 1 mg'ml), from about 0.01% to about 10% vitamin K2 MK7 (final concentration of about 50 - 100 mcg/ml), from about 0.001% to about 10% saturated dead sea salt solution, from about 0.01% to about 20% ginger essential oil, from about 0.01% to about 20% ginger extract, from about 2% to about 10% licorice root extract, from about 0.05% to about 15% polygonum multifloridum extract, from about 0.05% to about 15% cordyceps extract, from about 0.05% to about 15% bupleurum extract, from about 0.01% to about 3% kaempferia galanga essential oil, from about 0.01% to about.
- 5% lemon essentia! oil from about. 0.01% to about 5% eucalyptus essentia! oil, from about. 0.01% to about 15% rosemary essentia! oil, from about 0.01% to about 5% clove essential oil, from about 0.01% to about 5% cinnamon essential oil, from about 0.01% to about 5% cinnamon leaf essential oil, from about 0.01% to about 5% ravintsara essential oil, from about 0.01% to about 20% frankincense essential oil, from about 0.01% to about 20% myrrh essential oil, from about 0.01% to about 6% pine needle essential oil, from about 0.01% to about 10% lecithin, from about 0.001% to about 5% gallic acid, from about 0.001% to about 5% turmeric essential oil, from about 0.01% to about 30% macadamia nut oil, from about 0.01% to about 5% coconut oil, from about 15% to about 90% emu oil.
- These formulations may be particularly useful for treating alopecia.
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 5% to about 70% biosiiicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery of substances required for tissue repair, with biosilicates loaded with a 1 : 1 : 1 : 1 mixture of polygonum multifloridum (from about 0.05% to about 15% by volume), cordyceps extract (from about 0.05% to about 15% by volume), bupleurum (from about 0.05% to about 15% by volume), licorice root extract (from about 2% to about 10% by volume), from about 0.01 % to about 7% ubiquinof (final concentration of about 30 - 1000 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 5700 - 6500 rneg/ml), from about 0.01% to about 10% vitamin D (final concentration of about
- These formulations may be particularly useful for treating alopecia. They may be incorporated into hair loss scalp mask. In some of the embodiments, they may be massaged into scalp and left on for at least 30 minutes, ideally with exposure to heat to dilate scalp blood vessels (such as, e.g., via a near-infrared lamp).
- the invention is directed to a formulation comprising a mixture comprising, in % by volume, from about 5% to about 40% biosilicates loaded with at least one ingredient selected from the group comprising minerals, amino acids, vitamins and other bioactive compounds, e.g., for long-acting delivery of substances required for tissue repair, with biosilicates loaded with a 1 : 1 : 1 : 1 mixture of polygonum multifloridum (from about 0.05% to about 15% by volume), bupleurum (from about 0.05% to about 15% by volume), from about 0.01% to about 7% ubiquinol (final concentration of about 30 - 1000 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 5700 - 6500 mcg/ml), from about 0.01% to about 10% vitamin D (final concentration of about 3000 - 4000 IU/nil), from about 0.01% to about 10% vitamin E (final concentration of about 25 - 35 mg/ml of d
- sodium lauroyl lactylate nonionic surfactant derived from coconut oil and coconut milk, provides a soothing feel. These formulations are particularly useful for incorporation into shampoos and conditioners for the treatment of hair loss. In some of the embodiments, they may be massaged into scalp and left on for a sufficient amount time to allow absorption.
- a formulation comprises a mixture comprising, in % by volume, from about 1% to about 3% macadamia nut oil, from about 0.01% to about 0.2% coconut oil, from about 1% to about 3% lemongrass essential oil, from about 1% to about 3% German chamomile essential oil, from about 1% to about 3% Roman chamomile essential oil, from about 1% to about 3% provoke chamomile essential oil, and from about 80% to about 99% emu oil.
- These formulations may be particularly useful as a galactagogue preparation.
- they may be applied topically to axillae and upper chest (away from the nippies) to encourage milk production in breastfeeding mothers.
- a formulation comprises a mixture comprising, in % by volume, from about 5% to about 12% water extract of kaffir lime leaf, from about 10% to about 24% water extract of galangal, from about 5% to about 12% water extract of lemongrass, from about 0.1% to about 2% essential oil of kaffir lime leaf, from about 0.2% to about 4% essential oil of galangal, from about 0.1% to about 2% essential oil of lemongrass, from about 0.01% to about 2% of yuzu essential oil, from about 0.01% to about 2% of rosemary' essential oil, from about 2% to about 30% of blackseed essential oil, from about 2% to about 40% of fish oil, from about 0.01% to about 2% of palmarosa essential oil, from about 0.01% to about 2% of niaouii essential oil, from about 0.01% to about 2% of spearmint essential oil, from about 0.01% to about 2% of coriander seed essential oil, from about 0.01% to about 2% of ger
- a nut oil from about 0.5% to about 1% coconut oil and from about 30% to about 99% emu oil. These formulations may be particularly useful for treating diabetes/hyperlipidemia/obesity/coronary artery disease/metabolic syndrome/atherosclerosis/ hypertriglyceridemia. In some of the embodiments, they are administered orally (e.g., 1 gram every' morning).
- a formulation comprises a mixture comprising, in % by volume, from about 5% to about 75% frankincense essential oil, from about 5% to about. 50% myrrh essential oil, from about 5% to about 10% vanilla essential oil, from about.
- 0.1% to about 10% bitter orange essential oil from about 0.2% to about 12% essential oil of lemon balm (melissa), from about 0.1% to about 20% glycine (for a final concentration of about 0.5 g/ml to about 1 g/ml), from about 0.01% to about 2% of cinnamon essential oil, from about 0.01% to about 2% of lemon essential oil, from about 0.01% to about 2% of eucalyptus essential oil, from about 0.01% to about 2% of clove essential oil, from about 0.01% to about 2% ravintsara essential oil, from about 0.01% to about 30% of FDGE biosilicates loaded with compounds for tissue repair, from about 0.01% to about 2% of German chamomile essential oil, from about 0.01% to about 2% of lecithin, from about 0.01% to about 2% of flaxseed oil, from about 0.01% to about 0.05% of alpha !ipoic acid (final concentration from about 100 mg/ml to about 1000 mg/ml),
- formulations may be particularly useful for treating diabetes/hyperlipidemia/obesity/ metabolic syndrom e/hypertri glyceri demia/insuli n resistance/abnormal sleep debt/insulin resi stance/osteopenia/osteoporosis/anemi a of chronic disease, in some of the embodiments, they are administered orally (e.g., 1 gram every morning).
- a formulation comprises a mixture comprising, in % by volume, from about 5% to about 75% frankincense essential oil, from about 5% to about 50% myrrh essential oil, from about 5% to about.
- 10% vanilla essential oil from about 0.1% to about 10% biter orange essential oil, from about 0.2% to about 12% essential oil of lemon balm (rnelissa), from about 0.1% to about 20% glycine (for a final concentration of Ig/mi), from about 0.01% to about 1% of rosemary 1 essential oil, from about 0.01% to about 1% of cinnamon essential oil, from about 0.01% to about 1% of lemon essential oil, from about 0.01% to about 1% of cinnamon leaf essential oil, from about 0.01% to about 1% of eucalyptus essential oil, from about 0.01% to about 1% of clove essential oil, from about 0.01% to about 1% ravin tsara essential oil, from about 2% to about 5% macadamia nut oil, from about 2% to about 5%
- a formulation comprises a mixture comprising, in % by volume, cordyceps extract (from about 0.05% to about 5% by volume), bupleurum (from about 0.05% to about 5% by volume), from about 0.01% to about 5% ubiquinol (final concentration of about 30 - 1000 mg/ml), from about 0.01% to about 4% vitamin A (final concentration of about 5700 - 6500 meg/ml), from about 0.01% to about 10% vitamin D (final concentration of about 3000 - 4000 IXJ/ml), from about 0.01% to about 5% vitamin B3 (final concentration of about 500 - 4000 mg/mi), from about 0.01% to about 5% niacinamide (final concentration of about 500-4000 mg/ml), from about 0.01% to about 5% vitamin C (final concentration of about 1000 - 4000 mg/ml), from about 0.01% to about 10% vitamin E (final concentration of about 25 - 35 mg/ml of d-alpha to
- 10% vitamin K2 MK7 (final concentration of about 50 - 100 mcg/ml), from about 0.001% to about 10% saturated dead sea salt solution, from about 0.01% to about 20% ginger essential oil, from about 0.01% to about 20% ginger extract, from about 2% to about 5% licorice root extract, from about 0.01% to about 30% of rosemary essential oil, from about 0,01% to about 20% of cinnamon leaf essential oil, from about 2% to about 30% of blackseed essential oil, from about 2% to about 5% macadamia nut oil, from about 0.5% to about 1% coconut oil and from about 30% to about 99% emu oil.
- These formulations may be particularly useful for treating osteopenia, osteoporosis, and anemia of chronic disease. In some of the embodiments, they are administered orally (e.g., 1- 4 grams every morning).
- a formulation comprises a mixture comprising, in % by volume, from about 5% to about 20% of dead sea salt hydrated biosilicates, from about 10% to about 25% dead sea salt reconstituted with sterile filtered water, from about 10% to about 20% of grape seed extract (standardized to 95% proanthocyanidins), from about 10% to about 20% of grape skin extract (standardized to 95% proanthocyanidins), from about 10% to about 20% of resveratro! (standardized to at least 8% potency yield), from about 10% to about 20% of sterile filtered water, from about 5% to about 30% lecithin, from about 50% to about.
- a formulation may be made into capsules, to be taken orally from about 1 g - 4 g daily which may be particularly useful for improving neurologic function and reduce amyloid-beta peptide aggregation, prevent dementia, Alzheimer’s disease, and Parkinson ’s disease.
- a formula may be as described above, but formulated with 1000 ml vegetable glycerin in place of lecithin, to be administered as a nasal spray 1 ml spray 1 - 4 times daily to deliver bioactive ingredients close to the brain vasculature.
- the formulation may be diluted with a base composition to half the strength of the additional ingredients in the formulation.
- the formulation may comprise one or more exosome(s). Exosomes may, e.g., be loaded onto biosilicates (e.g., EDGE biosilicates) for, e.g., localized and/or extended release.
- biosilicates e.g., EDGE biosilicates
- Any of the formulations listed herein may include from about 1% to about 45% of Food Grade Diatom aceous Earth (EDGE) biosilicates or another pharmaceutically acceptable matrices.
- the biosilicates may be preloaded with one or more ingredient(s) to create a fraction which provide extended release of one or more ingredient(s).
- the formulation may be included into a topical preparation (e.g., a solution, an emulsion (e.g., an oil/oil emulsion), a cream, an ointment, or a balm).
- a topical preparation e.g., a solution, an emulsion (e.g., an oil/oil emulsion), a cream, an ointment, or a balm.
- the formulation may also be incorporated into a shampoo, conditioner, a mask, a face wash, a body wash, a cleanser, a toner, a wrinkle cream, an age spot fading cream, a serum, a dental preparation, a gum, floss, nasal spray, sunblock, self-tan product, a galactagogue preparation, a needle-tree vaccine, a needle-free medicine (e.g., transdermal insulin), a henna preparation, a moisturizer, a keloid and scar preparation, an eyelash and eyebrow
- an oral preparation to be taken internally to heal the gut lining in Ulcerative Colitis/Crohn’s Disease, irritable Bowel Disease, or a preparation for HIV mucositis, aphthous ulcers, diverticulitis, colitis, and other mucosal irritations an oral preparation to treat abnormal sleep debt, an oral preparation to treat osteoporosis, osteopenia, and anemia of chronic disease, an oral preparation to be taken internally to prevent or slow progression of a prediabetic patient from developing or progression of diabetes/obesity/hyperlipidemia/hypertriglyceridemi a/metabolic syndrome/atherosclerosi s/coronary artery disease, an oral preparation to improve insulin sensitivity, an oral preparation to be taken internally to prevent or slow progression of Alzheimer’s Disease, Parkinson’s Disease or Multiple Sclerosis, an oral preparation to prevent or slow 7 development or progression of cancer, an inhaled nebulized preparation, e.g., to treat,
- the formulation may also he an oral formulation.
- the formulation is administered orally and incorporates into membranes of gastrointestinal tract but is not absorbed into the systemic circulation, in other embodiments, the formulation is absorbed into the systemic formulation in an amount to provide an intended effect (e.g,, a therapeutically beneficial effect).
- the formulation may also be coated over a substrate.
- a substrate may e.g., a nanoparticle, a Food-Grade Diatomaceous Earth (FGDE) or a pharmaceutically acceptable matrix.
- FGDE Food-Grade Diatomaceous Earth
- the substrate may comprise a phospholipid, a ceramide, cholesterol, a fatty acid, an oil, a vitamin, a mineral, an amino acid, a hyaluronic acid, a fusogen, a biofermentation product of a faiit or plants, an additional therapeutic agent (e.g., a drug approved by U.S. FDA for use in humans), or a combination of two or more of the foregoing.
- the formulation may be, e.g., in the form of an ointment or another topical preparation, tor formulated to be administered orally, intranasally, intravenously, intramuscularly, during open surgeiy, as a suppository or via other routes.
- the fatty acid composition of the formulation may be adjusted using the base compositions and additional ingredients disclosed herein to render the formulation capable of crossing, integrating, modulating, regulating, or restoring cell membranes of the following cells: skin cells, brain cells, fibroblast cells, endothelial cells (cells lining the blood vessels), macrophages, immune cells, red blood cells, white blood cells, lymphocytes, leukocytes, hepatocytes, neurons, astrocytes, microglia, oligodendrocytes, bronchial endothelial ceils, respiratory interstitial cells, sustentacular cells, olfactory bulb neurons, adipocytes, dermal fibroblasts, muscle cells, cardiomyoeytes, pancreatic islet cells, Brunner’s gland ceil in the duodenum (secrete enzymes and alkaline mucus), all glandular cells, goblet ceils of the respiratory mucosa (secrete mucus), goblet cells of the digestive tract (secrete mu
- pancreas secrete pancreatic polypeptide
- salivary' gland mucous cells salivary gland serous cells
- Von Ebner’s gland cells in the tongue mammary' gland cells (secrete milk), lacrimal gland ceils (secrete tear), ceruminous gland cells in ear (secrete earwax), eecrine sweat gland dark ceils (secrete glycoprotein), eccrine sweat gland clear cells (secrete small molecule), apocrine sweat gland cells (secrete odoriferous secretions; are sex- hormone sensitive), gland of Moll cells in eyelid (specialized sweat glands), sebaceous gland cells (secrete lipid-rich sebum), Bowman’s gland cells in nose, olfactory epithelial cells, hair cells, hair follicle cells, endogenous stem cells of each organ, corti cotropes, gonadotropes, lactotropes, melanotropes, somatotropes, thyrotroprop
- the invention is further directed in part to a method of treating a disorder comprising administering a formulation comprising a mixture of fatty acids to a patient in need thereof in an amount and for a duration sufficient to alleviate one or more symptoms of the disorder in a patient.
- the mixture has a fatty acid composition that is substantially the same (i.e., approximate) as that of human skin and sebum.
- the invention is further directed to a method of treating a symptom of a disease associated with an injury, damage or dysfunction of a cellular membrane function in a mammal.
- the disease associated with a dysfunction, injury of damage of a cellular membrane function may, e.g., be pain, eczema, psoriasis, erythema, a bum, a cut, a bruise, a boil, a scar, a keloid, a non-healing wound, acne, rosacea, an allergy, an arthritis, an arthralgia, cancer, a neuropathy, a metabolic syndrome, an infection, a canker sore, an ulcer, Ulcerative Colitis (UC), a mucositis, diverticulitis, celiac disease, a colitis, Crohn’s Disease (CD), Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) atherosclerosis, Alzheimer’s Disease (AD), Parkinson’s Disease
- the symptom may, e.g., be selected from the group consisting of pain, inflammation, skin irritation, rash, a lesion, a wrinkle, hyperpigmentation, a keloid, a scar, pruritus, itching, indigestion, diarrhea, a cramp, cough, a bronchospasm, a discoloration, and combinations or two or more of the foregoing.
- the invention is also directed in part to a method of treating a disorder comprising administering a formulation comprising a mixture of oils, including animal oils and vegetable oils, to a patient in need thereof in an amount and for a duration sufficient to alleviate one or more symptoms of the disorder in a patient.
- the mixture has a fatty acid composition that is substantially the same (i.e., approximate) as that of human skin and sebum.
- the formulation is administered topically.
- the formulation may be administered orally, intranasally, intravenously, intramuscularly, during open surgery, as a suppository or via other routes of administration.
- the invention is also directed in part to a method of treating a disorder comprising administering a formulation comprising a mixture of naturally occurring compounds found in vegetable oils, animal oils, plant matter, mineral matter, exosomes, or other organic materials which have been subjected to fermentation (via bacteria, fungi, or other micro-organisms), e.g., in order to diversify and improve chemical activity of bioactive compounds, which have then been admixed or modified with a mixture of oils to improve delivery of such compounds to treat, improve or ameliorate a disease.
- a combination of therapeutics designed to address multiple aspects of a disease may be administered in conjunction via topical, oral, intranasal, intravenous, intramuscular, suppository ' or other routes such as, e.g., applied during open surgery'.
- the disorders that may be treated with the formulations of the present invention include but are not limited to the following: e.g., abnormal muscle tension, abnormal sleep debt, acne, alcohol withdrawal, allergies, alopecia, Alzheimer’s Disease (AD), angina/chest pain, aphthous ulcers, arthritis (e.g., rheumatoid arthritis, osteoarthritis, psoriatic arthritis, etc.), arthralgias induced by chemotherapy, arthralgias caused by autoimmune disease, arthralgias caused by trauma, asthma, atherosclerosis, anxiety, boils, bronchospasm, bruises, burns, canker sores, cancer, celiac disease, Chronic Fatigue Syndrome (CFS), Chronic Obstructive Pulmonary Disease (COPD), colitis, conjunctivitis, Coronary Artery Disease (CAD), cough, cramps/muscle spasms, Crohn’s Disease (CD), cuts in skin, depression, dermatitis, Diabetes Melli
- MS Multiple Sclerosis
- nasal inflammation neuralgia
- neuropathic pain neuropathy (numbness/paresthesias)
- nightmares non-healing wounds
- obesity otitis externa
- otitis media otitis media
- osteopenia osteoporosis
- anemia of chronic disease pain
- Parkinson’s Disease PD
- peripheral neuropathy pharyngitis, poor immune function, pre-menstrua!
- PMS pruritic rashes
- RLS Restless Leg Syndrome
- rosacea scars (including, e.g., keloid and atrophic), sciatica, senile !entigines, skin atrophy from overuse of topical corticosteroids, skin lesions, social anxiety, solar lentigines, strokes, sunburn, topical infections (impetigo, staphylococcal, streptococcal and fungal infections), ulcers, Ulcerative Colitis (UC), unspecified skin irritations, urticaria, vaginal atrophy, wounds, wrinkles, xerosis (dry skin), among others.
- Formulations can also be formulated to address or improve surfactant, production (such as would be useful in reducing atelectasis in patients who have recently undergone surgery); to facilitate lung maturity in neonates, to address acetylcholine deficiency, to improve nutrient absorption, slow down aging by decreasing free radical production and inflammation, decrease risk for or progression of cancer by decreasing free radical production and inflammation, and decrease risk of acute infarctions of the brain and myocardium (e.g. stroke and heart attacks) by improving atherosclerosis.
- surfactant production
- production such as would be useful in reducing atelectasis in patients who have recently undergone surgery
- to facilitate lung maturity in neonates to address acetylcholine deficiency, to improve nutrient absorption, slow down aging by decreasing free radical production and inflammation, decrease risk for or progression of cancer by decreasing free radical production and inflammation, and decrease risk of acute infarctions of the brain and myocardium (e.g. stroke and heart attacks) by improving atherosclerosis.
- the formulation is administered topically.
- the formulation may be administered, intranasally, intravenously, intramuscularly, during open surgery', or a suppository', or via a spray.
- Figure 1 Pain is a Multifactorial Problem, (image obtained from https://st.depositphotos.eom/1812149/2267/i/450/depositphotos__22674323-stock ⁇ photo-full ⁇ body-pain, jpg)
- Figure 2 Chemical Structure and 3-D Modeling of a Phospholipid, (obtained from htps://classconnection.s3.amazonaws.com/624/flashcards/377l624/gif71164999854bd- I43EF30B3E26DF055A4.gif)
- FIG. 3 Schematic Representation of a Phospholipid, (obtained from htps :/7s3-u s- west-2.amazonaws.com/courses-images/wp- content/uploads/sites/1842/2017/01/26154139/figure-05-01 -0Sa.jpeg) [00109]
- Figure 4. Phospholipids self-assemble into bi!ayer structures or micelles, (obtained from https://qph.fs.quoracdn.net/main-qimg-2417fafb8e6c3b90319bc5675c5a32c3-c)
- Phospholipids can form micelles and liposomes (which can serve as carriers of therapeutic molecules, including transmembrane proteins) as well as bilayer sheets which form the cell membrane, (obtained from https://3. bp.bJogspot.com/- 8TKWDN8] Y 5 g/UDhU0b3NbEI/AAAAAAAABR4/fkcPx9Tj Qss/s 1600/F02-20. JPG)
- Figure 6 3 D model of a human cell, cut in half to reveal cell contents. Note the phospholipid bilayer forming the cell surface/cell membrane (peach-color), (obtained from https://statie.turbosquid.com/Preview/2014/05/19 18 04 31/human%20cell%20max%202.j pgd9d481 ff-258d-4a3b-8b31 -fd0373 c 15409HDJ pg)
- FIG. Section of Human Cell Membrane Showing Transmembrane Proteins, (obtained from https://pixfeeds.com/images/21/511840/120Q ⁇ 86007545 ⁇ ceil ⁇ membrane.jpg)
- FIG. 10 Simplified Schematic of Cell Signaling with Transmembrane Receptors.
- Figure 11 A ligand (a chemical messenger from outside of the cell) binds when receptors find their counterpart, generating signals that reach into the cell to direct the cell’s command center, the nucleus to act (for example, directing the cell to grow- out of control).
- Figure 12 Multiple chronic diseases are associated with abnormal cell lipid composition.
- Figure 14 Exogenously supplied phospholipids, sphingoiipids, and fatty acids incorporate into cell membranes, raising the threshold required for cell signaling.
- Figure 15. Exogenously supplied phospholipids, sphingolipids, and fatty acids confer therapeutic compounds with the ability to cross the normally hydrophobic cell membranes. Once inside the cell they can direct the command center of the cell (the nucleus) to calm inflammation, to shut down cancer genes, etc.
- Figure 16 Many types and shapes of diatoms. Photo Reference Credit to Kent Wood, Photographer, (obtained from http://www.illinoisscience.org/wp- content/uploads/2017/ll/diatom-007-24QQ-copy.jpg)
- Figure 17 Example of a diatom with intricate 3-dimensional structure and pores useful for complexing multiple compounds. Photo Reference Credit to Steve G. Schmeissner, photographer, (obtained from http://3.bp.blogspot.com/- qAQfLhi8Ty8/Ubs7sgBjXDI/AAAAAAAAAeo/ANMfoJ2FHQw/s320/26-diatom-sem-steve- gschmei ssn er.j pg)
- Figure 18 Loading of diatoms with minerals, amino acids, vitamins, and bioactive compounds, then coating them with substances that confer penetrability of human skin as well as cell membranes.
- Figure 19 Time release of therapeutic substances into the skin, as well as past the cell membrane. Delivery of these raw' materials facilitate cellular and tissue repair.
- Figure 20 Scanning Electron Microscopy Image of Unloaded Diatom with Schematic. Photo Reference Credit to Steve G. Schmeissner, photographer, (obtained from http ://3.bp .bJogspot.com/- qAQfLhi8Ty8/Ubs7sgBjXDI/AAAAAAAAAeo/ANMfoJ2FHQw/s320/26-diatom-sem-steve- gschmeissner.jpg)
- Figure 21 Schematic of Diatom, With Many Open Pores. Demonstration of an amino acid nestling inside a pore.
- Figure 22 Schematic of A Diatom Being Loaded with Multiple Active Ingredients.
- Figure 23 Schematic of A Diatom Releasing Multiple Active Ingredients Over >2 Weeks.
- Figure 24 Additive Effects of Long-Term Fraction (Biosilicates Loaded with Active Ingredients).
- Figure 26 Totipotent Stem Cells from Embryos Give Rise to Pluripotent Stern Cells Capable of Generating Multiple Ceil Types (obtained from http s : /7ih 5. googl eu sercontent . coni/- jZ3YrRhTVRU/TXhVpt4GvxFAAAAAAAAAB4/pJoGVRefPwk/sl600/pluripotent-stem- ceils.jpg)
- Figure 27 Reprogramming of Somatic Cells to A Pluripotent Stem Cell Using 4 Transcription Factors (Yamanaka Transcription Factors)
- fatty acid composition of a formulation as used herein means that the formulation contains fatty acids of the type and in the amounts that allow the formulation to cross and/or integrate into a membrane or organelle of a cell or modulate a function of an exosome.
- substantially similar and “substantially identical” and “substantially the same” encompasses fatty acid compositions that are identical to that of a membrane of a cell or an organelle; and the fatty acid compositions that are not identical to that of a membrane of a cell or an organelle but still allow the formulation to cross and/or integrate into a membrane of a cell or an organelle and/or modulate a function of an exosome.
- a fatty acid composition that is “substantially similar” or “substantially identical” or “substantially the same” to that of a membrane of a ceil or organelle as used in the present specification is different from and does not encompass the fatty acid composition of emu oil, as it, e.g., comprises a higher amount of oleic acid times than emu oil (e.g., at least 1.5 to 2 times higher) than the emu oil.
- an organelle refers to a lipid-bilayer enclosed subceliular differentiated structure within a cell which performs a specific function.
- An organelle is usually visible under the microscope as a distinct structure or object. Examples would include ribosomes, mitochondria, vacuoles, etc.
- exosome as used in the present specification means a membrane bound extracellular vesicle.
- an essential oil as used in the present specification means a volatile oil or mixture of volatile oils and other substances obtained by chemical extraction from a plant which typically has a characteristic odor or flavor of the plant from which it is obtained.
- Essential oils may be obtained from just one part of the plant (for example, essential oil of ginger root, vs essential oil of bay leaves).
- Essential oils may be different depending on the solvent used to extract the bioactive compounds - for example, CG2 extraction vs aqueous extraction vs alcohol extraction may yield different mixtures or proportions of bioactive compounds from the same plant.
- short chain fatty acid or “short chain triglyceride” as used in the present specification means that the fatty acid or triglyceride contains less than 6 carbons.
- medium chain fatty acid or “medium chain triglyceride” as used in the present specification means that the fatty acid or triglyceride comprises between 6 and 12 carbons.
- long-chain fatty acid or “long chain triglyceride” means that the fatty acid or triglyceride contains more than 12 carbons.
- MCT oil medium chain triglycerides
- C6 caproic acid
- C8 caprylic acid
- CIO capric acid
- lauric acid lauric acid
- liquid skin refers to an embodiment of a base composition in an inventive formulation.
- vehicle liquid skin refers to an embodiment of a base composition in an inventive formulation.
- high oleic acid sunflower seed oil means sunflower oil comprising at minimum 80% oleic acid.
- sunflower seed oil means sunflower oil comprising about 20% oleic acid.
- the invention is directed in part to a delivery system comprising a mixture of fatty acids.
- the mixture comprises emu oil.
- Emu oil possesses a high concentration (up to 47%) of oleic acid in addition to other naturally occurring substances which result in anti-inflammatory properties useful in the treatment of pain and other inflammatory illnesses.
- the composition by percentage of fatty acids from Emu show's that it is quite comparable to that of human skin (See Table 2A and Table 2B), with the exception of a slightly higher percentage of oleic acid (47%) vs 31% for human skin. This similarity in composition to human skin renders it capable of serving as a carrier for other lipid as well as aqueous ingredients.
- emu oil may be combined with a selected mixture of vegetable oils composed to mimic the fatty acid profile of human skin and sebum (hereinafter, “Liquid Skin”) that can be admixed with medicinally active compounds such that they incorporate into existing skin ceils or may be used as raw material for creating new ' cells.
- Liquid Skin a selected mixture of vegetable oils composed to mimic the fatty acid profile of human skin and sebum
- Vegan Liquid Skin by using a mixture of vegetable oils to approximate the fatty acid profile of human skin and sebum.
- “Liquid Skin” in the present disclosure encompasses both types of mixtures.
- the invention is directed in part to a mixture of various oils to mimic or restore or modulate the fatty acid profile of healthy human skin and sebum, which can be customized to deliver medicinally active compounds for the treatment of multiple diseases.
- Phospholipids are phosphorus-containing lipids composed of a fatty acid, a phosphate group, a glycerol, and a simple organic molecule such as choline; they are the basic building block of cell membranes, as seen in Figure 2.
- phospholipids are typically represented as a ball-like structure with two tails in most diagrams, as seen in Figure 3.
- phospholipids can self-assemble in water into organized bilayer structures or even micelles (spheres).
- the cell is essentially a giant double-layered liposome (See Figure 6), which houses many smaller organelles “mini organs” which are the machinery' of the cell (akin to lifting up the hood of a car to see the parts that make up an engine) including the cell nucleus (seen in yellow in Figure 6) which is the command center of the cell housing the deoxyribonucleic acid or DNA (think of the nucleus as the hub that directs the organelles how to function, what proteins to make, etc.).
- Any cell can individually activate specific DNA sequences to make proteins that cause the cell to signal to other cells. If the DNA sequences become activated out of sequence or lose their system of checks and balances, then cancer or other diseases may result.
- the cell surface is critical for how signals from outside the cell make its way into the cell nucleus to change the activity and function of the cell.
- a healthy cell membrane is required for signals from within the cell to be sent appropriately into the environment outside of the ceil.
- One cell’s signaling has the ability to alter the activity of other ceils locally or in remote locations.
- this cross section of a cell shows the EGFR (Epidermal Growth Factor Receptor) embedded in the ceil membrane ( Figure 9).
- EGFR is important in ceil proliferation. Dysregulated EGFR signaling leads to unregulated cell growth, cancer, and metastases.
- the cell membrane is the site where signals from the outside environment are interpreted and translated into directions that drive that cell’s behavior.
- a healthy cell membrane is composed of a mixture of lipids, proteins, and sugars, (See Figure 7) organized into regional domains (commonly called “lipid rafts”) that serve to signal for multiple aspects of cell behavior such as growth, cell division, pain, cell differentiation, or cell death (PMID 31052427).
- PMID 31052427 Specific sub-compartments of the cell possess different lipid compositions (PMID 31052427), which when altered due to diet or genetic defects lead to alterations in cell function, metabolism, and ultimately to chronic disease such as cancer (PMID 30518103), diabetes (PMID 29462590, 28742512), Alzheimer’s Disease (PMID 31379503), neuroinflammation (PMID 31862695) and altered pain processing (PMID 31862695, PMID 29459435) as just a few examples.
- cancer PMID 30518103
- diabetes PMID 29462590, 28742512
- Alzheimer’s Disease PMID 31379503
- neuroinflammation PMID 31862695
- PMID 29459435 altered pain processing
- Fatty acids and other plant-derived compounds have an ability to insert into the human cell membrane.
- n-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA); as well as plant-derived polyphenolic and terpenoid phytochemicals such as curcumin (diferuloylmethane) possess the ability to span the ceil membrane and disrupt ceil signaling.
- EPA, DHA and curcumin were used separately or together in one study, they reduced the number of atypical/precancerous stem ceils in an animal model of colorectal cancer (PMID 16475686, 29860560).
- the proposed mechanism was the disruption of the lipid rafts (regions of the cell surface enriched in signaling proteins) necessary for transmembrane signaling.
- Liquid Skin a blend of oils to approximate the fatty acid composition of human cell membranes and sebum
- a medical condition e.g., pain
- disrupting the signaling that occurs at the cell surface by inserting into the cell membrane decreasing the likelihood of the paired or multimeric receptors interacting with each other (See Figures 10-14).
- Transmembrane receptors migrate along the surface of the cell in multiple directions according to Brownian Motion (a random movement of microscopic particles suspended in liquids or gases resulting from the impact of molecules of the surrounding medium), but in this case restricted to the plane of the cell membrane surface until they encounter an appropriate counterpart. Once dimerized (see the transmembrane protein-protein interaction in Figure 11) or multimerized (formation of a multi-protein cluster) new ? signaling receptor docking sites may form (See Figure 12).
- TRP transient receptor potential channels
- TRP channels are a superfamily of transmembrane ion channels that become activated in response to chemical or physical stimuli which ultimately signal for pain.
- These channels are made up of four subunits which are embedded on the cell surface in the cel! membrane. The four individual subunits must find each other to lock into formation, resulting in a dover-leaf-Hke pattern before the channel can form in the cell surface to allow ions to flow through, signaling pain.
- the chances that the four submits find each other and bind to form the channel decreases (See Figures 13-14 for an example of exogenous phospholipids decreasing changes of transmembrane protein interaction and reduced intracellular signaling).
- the net effect is to increase the pain threshold for a patient, as it would require a longer time for chance encounter of pain receptors to multimerize and allow' for docking.
- the mechanism targeted by this invention does not activate the mu opioid receptors, which are associated with the unwanted side effects of respiratory depression (which frequently can lead to unintentional death), as well as decreased heart rate, nausea, and constipation.
- exogenous phospholipids and other lipid mixtures like Liquid Skin can be used to confer penetrability to nanoparticles such as naturally occurring biosilicates such as Food Grade Diatomaceous Earth (FGDE).
- FGDE are biocompatible, nontoxic porous biosilicate skeletal remains of unicellular diatom microalgae that measure between 1.9 pm to 180 pm.
- FGDE is safe to consume but hazardous to work with when dry.
- an N95 mask must be worn to cover the nose and mouth when handling it in a well-ventilated space to prevent interstitial lung disease from silicosis.
- FGDE When taken orally after it has been coated, FGDE will pass through the digestive tract unchanged and does not enter the bloodstream.
- Diatoms do not penetrate the skin when applied to the skin as a day paste, unless coated with substances that confer penetrative properties. The diatoms are possessed of many pores and have complex 3-dimensional architecture, ideal for loading multiple bioactive compounds (Figure 17).
- the invention is directed in part to diatoms hydrated in a dead sea saltwater solution to render the surface of the diatoms able to form bonds and to load minerals, hi some of these embodiments, the hydrated diatoms are sequentially loaded with amino acids, vitamins, and other bioactive compounds (See Figures 18-19, and 20-22) and then coated with a mixture of oils which will confer ability to penetrate the skin and the cell membrane ( Figure 18-19).
- hydrated diatoms may be loaded with one bioactive ingredient; mixtures of these individually loaded diatoms may be combined to provide benefit in the target disease.
- the hydrated, coated and loaded diatoms release the loaded compound(s) and provide a therapeutic effect, e.g., for a duration from about 5 seconds to 8, or more, weeks (See Figure 23). In some embodiments, it takes about 2 to 4, 2 to 6 or 2 to 8 weeks or longer for the loaded components to dissociate from the nanoparticle (See Figures 23-24),
- the invention is also directed in part to the use of natural biosilicate nanoparticles (Food Grade Diatomaceous Earth, or FGDE) as a delayed-release delivery system for multiple bioactive compounds, and then coating these loaded particles with Liquid Skin to confer the ability to penetrate the skin as well as the ceil membranes for the purpose of delivering compounds that alter cell function and/or alleviate and reduce severity of one or more symptom(s) of a medical condition (See Figures 18-19) .
- natural biosilicate nanoparticles Food Grade Diatomaceous Earth, or FGDE
- FGDE Food Grade Diatomaceous Earth
- coated nanoparticles may penetrate the skin into the intercellular space while other coated nanoparticies may penetrate past the cell membrane into the cell.
- Both sets of nanoparticies wall slowly deliver vital nutrients such as minerals, amino acids, vitamins important for tissue regeneration and repair, coupled with bioactive compounds that facilitate healing and stem cell regeneration over, e.g., at least 2-4 weeks (See Figures 18-19),
- the diatoms are added in a proportion that makes them the rate-limiting component to ensure that every diatom will be coated, and that a large proportion of the preparation will be immediate-acting (e.g. an active compound surrounded by lipid mixture conferring penetration into the skin and the cell membrane, See Figure 15).
- the lipid coating which permits tissue penetration may play an additional role: that of adding into the cell membrane surface to raise the threshold for signaling for pain (Figure 15 and Figure 19).
- the loaded components held by reversible bonds may be released gradually for, e.g., a duration from about 1 minute to 8, or more, weeks (e.g., for at least 2-8 weeks); while the components coated with lipid coating may confer immediate action.
- Each application of the preparations may have an additive effect due to long duration of action (See Figures 23-24), Thus, for example, the goals of immediate relief from pain and inflammation are achieved, while providing long-term release of active elements required for tissue regeneration and repair over a number of w ? eeks. With each application the patient will build more nutrients only in the area that needs restoration and healing (See Figure 24). Side effects, if any, will be limited due to the local, non-systemic application.
- the percent lipid composition of pooled human sebum analyzed by thin-layer chromatography was as follows: ceramkles (13%), fatty acid (47%), cholesterol (7%), cholesterol esters (2%), squalene (11%), triglycerides (3%), and wax esters (17%) (PMID 12677098) with approximately 50% as phospholipids.
- the preparations of the invention follow these ratios, with adjustments to components made depending on the disease being targeted.
- the fatty acid composition of the invention mimics the fatty acid composition of healthy human sebum and/or subcutaneous fat.
- the composition of healthy human sebum and subcutaneous fat, along with composition of some oils, is provided in Table 2A and 2B.
- the formulation comprises a mixture of oils to match a fatty acid composition of human sebum, human cell or human diabetic ceil as provided in Table 2A.
- the oils for inclusion in the mixture may be selected from the oils listed in Table 2B, or other oils.
- the oils are combined in specific amounts to provide a fatty acid composition that is different from a fatty acid composition of the individual oils used and is better suited for an intended purpose.
- the formulation may comprise a mixture of (i) macadamia nut and coconut oil and (ii) emu oil or high oleic sunflower seed oil.
- the addition of macadamia nut and coconut oils to either emu oil or to high oleic sunflower seed oil results in a fatty acid composition comprising oleic acid concentration that is substantially identical to (or higher) than the concentration of oleic acid in human cell membranes, and may therefore facilitate and/or improve permeability of the formulation and its components into cell membranes and/or into the subcellular spaces and/or into the subcellular organelles of a mammalian cell.
- the addition of macadamia nut and coconut oils to either emu oil (as in liquid skin) or to high oleic sunflower seed oil (as in vegan liquid skin) increases the oleic acid at minimum 5-fold that of human cell membranes, resulting in greater penetrability of admixed therapeutic substances into the cell membrane, into the subcellular space, or into the subcellular organelles of a mammalian cell (e.g., a mammalian ceil). Higher concentrations of oleic acid may be required to penetrate into the subcellular organelles (e.g., to directly influence cellular metabolism) because the compounds must cross more than one set of cell membranes.
- the composition comprises emu oil.
- Emu oil may comprise, in % by volume, from about 1% to about 99%, from about 2% to about 99%, from about 5% to about 98%, from about 10% to about 96%, from about 15% to about 96%, from about 20% to about 95%, from about 25% to about 95%, from about 30% to about 95%, from about 40% to about 95%, from about 45%o to about 95%, from about 60% to about 95%.
- the invention is directed in part to the use of a blend of organic vegetable oils to achieve a profile similar to that of the composition seen in healthy human skin and human subcutaneous adipose (PMK) 23878791).
- PMK human subcutaneous adipose
- the fatty acid profile of the formulation may be optimized for specific diseases intended to be treated by the formulation and route of administration.
- the formulation may comprise organic high-oleic sunflower seed oil, with a high oleic acid content of 75-91% and used as a topical preparation useful In stimulating peripheral neuronal growth, since oleic acid is a necessary component of myelin sheath formation for neuronogenesis (the formation of new neurons in an adult human).
- Some of the vegetable oils that can be used in the formulation of the invention are listed in Table 2B, above, and include olive oil, due to the additional benefits of polyphenols (antioxidants), vitamins, and essential fatty acids present in this healthful oil, as well as flax seed oil and coconut oil.
- Oleic acid is postulated to be the fatty acid most responsible for the superior penetration properties of emu oil, which confer its penetration properties upon substances intermixed in it.
- Emu oil has been demonstrated to penetrate and to carry? active ingredients (PIMD 27178879, RM ⁇ PR 28527394) around 3 mm into human skin, by destabilizing the alpha-helix structure of keratin (PMK) 28527392), interacting with fats in the skin (PMK) 28527394), and promoting restructuring of skin (PMID 15837639, PMID 15567771, PMID 27069472).
- Application of pure emu oil alone has been found to have anti-inflammatory, and thus analgesic effects.
- This effect may be improved, in the present invention, upon modifying the fatty acid composition of emu oil, e.g., by blending emu oil with one or more additional oil(s) (e.g., vegetable oils) to make the profile to more closely resemble that of a human or mammalian cell membrane, a cell, an organelle, or an exosome, depending on the intended target.
- additional oil(s) e.g., vegetable oils
- emu oil in combination with one or more additional oil(s) in accordance with the present invention may be used to shift white blood cells from a pro-inflammatory Ml phenotype to an anti-inflammatory M2 phenotype.
- emu oil in combination with one ore additional oil(s) may be used to upregulate stem cell markers Sox-2, Nanog, Oct4, K114, and c-Myc, which possess the ability to reprogram differentiated skin cells back into a stem cell-like progenitor state.
- This property alone may be useful in hastening recovery' times for injured skin or for maintaining youthful and healthy skin. It could also be useful in the treatment of cancer (in which reprogramming of cancer stem ceils into a naive stem cell-like state could result in selective apoptosis of cancer stem cells (normal stem cells which have sustained damage and become transformed to give rise to tumor-forming cells).
- every' ingredient of the formulation is considered an active ingredient, as it benefits the body by addressing, e.g., specific aspects of pain.
- oleic acid plays a significant role in allowing superior delivery' of substances into the human body, it also decreases anger (treating one of the emotional aspects of pain) w'hile increasing mitochondrial function (PMID 23446891), decreases intracellular oxidative stress (PMID 31802387) thus decreasing inflammation and swelling, thus decreasing pain.
- FGDE loading technology as described above may be used to create loaded nanoparticles that facilitate delayed release of active compounds to injured or affected tissues
- FGDE loading technology in accordance with the present invention is not limited to pain but may be modified as needed for the specific disease being treated. Addition of instant-acting active compounds rounds out the design to permit immediate relief from pain, in addition to delayed release for prolonged relief from pain for example.
- the invention encompasses various formulation which pay be used for treatment of pain, including vegan, non-vegan, prescription strength, and over-the-counter preparations.
- the present invention provides a formulation for treatment of pain.
- the formulation may, e.g., comprise i. (Any of the Pain Formulations described herein +ULDN) - in certain embodiments, this will be prescription strength which incorporates ultra-low dose naltrexone.
- ULDN ⁇ 1 ug daily per dose. See Table 1 for low dose naltrexone. ii.
- the formulations may be used for different types of pain, including, for example, osteoarthritic pain, pain from rheumatoid arthritis, neuropathic pain, superficial pain, muscle aches, headaches, etc.
- the formulation may he used to treat superficial muscular pain and tension by an application of the formulation to an affected area.
- the formulation may be used to treat deep muscle, joint or ligament pain and tension by an application of the formulation to an affective area.
- the application of the formulation may be preceded and/or accompanied and/or followed by an exposure to a Red/Near Infrared Lamp.
- the exposure may, e.g., be from 600nm to 1 lOOnni, or from 600nm to 250Qnm.
- Exposure to light within this range of wavelengths may stimulate stem cells, improve metabolism by activating chromophores within the cell, stimulate increases in electron transport, in mitochondrial membrane potential and ATP production, in dilation of blood vessels >400% to facilitate influx of immune cells, all which improve cell survival, increase proliferation and migration of stem cells, leading to expedited wound healing, decreased pain, decreased oxidative stress and inflammation (PMID 28748217), Use of a Red/Near Infrared Lamp from approximately 10 inches away from target tissues for approximately 30 minutes or longer, as tolerated, will further augment the effect of a formulation which contains Liquid Skin by increasing absorption and bioactivity via the mechanisms outlined above (PMID 28748217).
- the invention provides a massage oil comprising a diluted version of any of the pain formulations listed above.
- the concentration of the diluted formulation is from about 5% to about 90% of the pain formulation listed above (e.g., 10% of any of the pain formulations listed above (e.g., the formulations described above for infants)).
- the massage oil may be used during lymphatic drainage and/or acupressure massages.
- the formulation may further comprise palmitoylethanolamide (5% ⁇ 30% by volume) with alpha lipoic acid (0.05% - 15% by volume) as these both synergize with myrrh (0.0005%-l% by volume) for analgesia (PMID 30696240).
- palmitoylethanolamide and alpha lipoic acid may ⁇ be used.
- the invention provides a formulation for treating neuropathy as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the invention provides a formulation for treating hair loss as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above. This may be applied to the scalp, with effects potentiated by application of near infrared light from approximately 10 inches away from the scalp, for approximately 30 minutes or longer, as tolerated.
- the invention provides a mask formulation for treating hair loss as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above. This may be applied to the scalp, with effects potentiated by application of near infrared light from approximately 10 inches away from the scalp, for approximately 30 minutes or longer, as tolerated.
- the invention provides a shampoo formulation for treating hair loss as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the shampoo can also be used as a hair mask - lathering up but then allowing it sit on the scalp to let the long-acting fraction soak into the scalp.
- the invention provides a scalp serum for treating hair loss as described above, which may be applied directly to the scalp, and further augmented by application of a near infrared light from approximately 10 inches aw-ay from the scalp, for approximately 30 minutes or longer, as tolerated, in certain embodiments, after the serum is applied, the hair could be washed with a shampoo, e.g., in accordance with the invention, and treated with a conditioner, e.g., in accordance with the invention.
- the invention provides a formulation for improving skin texture, health, and cellular regeneration as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the invention provides a formulation for moisturizing the skin, and with ingredients to improving skin texture, health and cellular regeneration as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the invention provides a formulation for moisturizing the skin, and with ingredients to improving skin texture, health and cellular regeneration as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the invention provides a formulation for moisturizing the skin, and with ingredients to improving skin texture, health and cellular regeneration as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the formulation may be diluted 10% in Rosewater and sprayed onto the face as a toner.
- the invention provides a formulation for moisturizing the skin, and with ingredients to improving skin texture, health and cellular regeneration as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the formulation may be diluted 10% and include pi an t-b ased surfactants .
- the invention provides a formulation for fading hyperpigmented spots as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above,
- the invention provides a formulation for moisturizing the skin, and with ingredients to improving skin texture, health and cellular regeneration as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the formulation may be diluted to 20% in sea kelp bioferment and used as a night serum.
- the invention provides a formulation for providing a higher concentration of ingredients in a higher concentration of FDGE to allow extended release of ingredients for improving skin texture, health and cellular regeneration as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- This mask can be applied to the face, body, or scalp, with or without heat and may be rinsed off after absorption for about 20-30 minutes.
- a bath mud formulation is the same as the mask formulation.
- a thin coat of the formulation may be applied over exfoliated skin of the body and face and allowed to dry' in a hot sauna or with heater in the bathroom. After mud has entirely dried the formulation is rinsed off, and, in certain embodiments, may reveal rejuvenated skin.
- the invention provides a formulation for locally providing nutrients important for regeneration of burned or wounded skin when applied to intact skin adjacent to injured or burned skin as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above. These formulations may be used in conjunction with exosomes and medical honey to facilitate regeneration and to prevent infection.
- the bum/wound formulation may be loaded onto porous bandages to be placed on intact skin surrounding a wound area but for safety precautions will not be applied directly to the wounded skin.
- the invention provides a formulation for preventing and treating acne.
- the formulation comprises the basic composition and one or more additional ingredients as described above. These formulations may include ingredients which suppress p. acne without inducing antibiotic resistance, as described above.
- the invention provides a formulation for treating rashes, including eczema, psoriasis, and nonspecific dermatitis or skin eruptions as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the invention provides a formulation for reducing IL-4 mediated mast cell degranulation thus reducing itchiness and allergic response associated with rashes, including eczema, psoriasis, nonspecific pruritus, and urticaria as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the invention provides a formulation for treating pain and increased muscle tension at rest as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the formulation may be applied to the lower abdomen for the treatment of premenstrual syndrome (PMS), for example.
- PMS premenstrual syndrome
- the invention provides a formulation for stimulating milk production as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the invention provides a formulation for treating pain as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the formulation may be used with near infrared light 5-15 minutes per joint as described above.
- the invention provides a formulation for preventing and treating skin infections as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the invention provides a formulation for preventing and treating infections as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above. Several drops of this formulation may ⁇ be applied to ribbon floss prior to flossing to prevent and treat gingivitis.
- the invention provides a formulation for improving transdermal penetration of other substances as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- a half-bubble sticker filled with Liquid Skin plus a vaccine or medication e.g, insulin
- a vaccine or medication e.g, insulin
- the invention provides a formulation for improving transdermal penetration of other substances as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the formula may form 25% of the final concentration, with concentrated black tea and henna forming 75% of the final concentration. This pigmenting solution may be applied evenly to exfoliated skin and allowed to set for 2 hours to provide the appearance of tanned skin, without the associated skin damage caused by ultraviolet radiation.
- the invention provides a formulation for improving transdermal penetration of other substances as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the formula may form from about 25% to about 30% of the final volume, with carrot seed oil (SPF 35-40) forming from about 25% to about 30% of the final concentration, with red raspberry seed oil (SPF 25-50) forming from about 25% to about 30% of the final concentration for immediate acting sunscreen properties.
- the addition of FGDE diatoms loaded with carrot seed and red raspberry seed oils may be considered for a longer-lasting time-released natural sunblock effect.
- the invention provides a formulation for improving transdermal penetration and retention of other substances as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the basic composition may comprise from about 25% to about 30% of the final volume, with henna forming from about 70% to about 75% to lead to longer- lasting designs.
- the formulation may be applied to the skin and allowed to absorb for a few 7 minutes prior to applying henna designs.
- the invention provides a formulation for moisturizing the skin, and with ingredients to improving wound healing, skin texture, health and cellular regeneration as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- This formulation may be applied to intact skin surrounding a newly placed tattoo to deeply moisturize and to optimize tattoo integrity and healing while minimizing scarring. Keloid and Scar Preparation
- the invention provides a formulation for improving wound healing, skin texture, health and cellular regeneration as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above. Application of this formulation may result in improvement in the appearance of scars.
- the invention provides a formulation for improving healing of the injured mucosa of the gastrointestinal tract when taken internally, as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above. Capsules with different dissolving coefficients may be used to target the proximal, intermediate, and distal regions of the gastrointestinal tract.
- the invention provides a formulation for providing bioactive compounds required for muscle relaxation when applied topically, as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- Diabetes/Hvperlipidemia/Obesitv/Hvpertriglyceridemia/Metabolic Syndrome Formula
- the invention provides a formulation for improving insulin resistance, hyperlipidemia, hyperglycemia and hypertriglyceridemia when taken internally, as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the invention provides a formulation for improving insulin resistance, hyperlipidemia, hyperglycemia, hypertriglyceridemia, obesity, metabolic syndrome, abnormal sleep debt, osteopenia, osteoporosis and anemia of chronic disease when taken internally, as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above Abonormal Sleep Debt Formula 1
- the invention provides a formulation for reducing abnormal sleep debt when taken internally, as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above
- the invention provides a formulation for improving insulin resistance, hyperlipidemia, hyperglycemia, hypertriglyceridemia, obesity, metabolic syndrome, abnormal sleep debt, osteopenia, osteoporosis and anemia of chronic disease when taken internally, as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above
- the invention provides a formulation for improving lesions of the mucosa when applied topically, as described above.
- the formulation comprises the basic composition and one or more additional ingredients as described above.
- the invention provides a formulation for improving pitting edema and/or lymphedema when applied topically, as described above.
- Pain Preparation 1.0 to signify preparation for pain, version 1.0, 2.0 for the next iteration, etc.
- PP1 was 5ml of German chamomile essential oil in 4 fluid ounces of emu oil, mixed thoroughly.
- German chamomile essential oil over Roman chamomile essential oil
- Emu oil was used for its ability to penetrate deeply and deliver ingredients admixed therein.
- the formulation was also found to be effective for relieving insomnia, which is believed to be due to the formulation’s mild anxiolytic properties.
- the formulation was also found to be effective in a patient with chronic neck pain from multiple neck injuries who had no history? of neck surgery ? .
- the patient used PP1, the near infrared (NIR) light, along with other natural methods of pain management, and found it effective for the treatment of pain.
- NIR near infrared
- PPI was also tried in a patient with intractable neck pain status post multiple neck surgeries who was looking for a natural topical solution for the pain.
- the patient had tried opiate pain pills and patches to no avail.
- the patient applied PPI to her neck and found it effective for pain relief shortly after application.
- PPI could be used alone, or in conjunction with a near-infrared (NIR) lamp (from approximately 600mn to 2500nm.
- NIR near-infrared
- the NIR lamp may be used, e.g., to dilate blood vessels and increase local blood flow to >400% within seconds of applying the light, -'TO inches from the skin, for 5-60 minutes at a time or as tolerated (PMID 28935419).
- PPI had a distinctive odor.
- PP2 versions comprised 20-30 drops (1-1.5 ml) of German chamomile oil, with the addition of 40 drops (2ml) premium cold-pressed orange essential oil, 10 drops (0.5ml) peppermint essential oil, and 10 drops (0.5ml) Bridal Garden Jerusalem Anointing Oil by www.thenewjerusalem.co. The remaining balance rvas Emu oil up to a final volume of 1 fluid ounce. 12 bottles of PP2 were distributed to 12 subjects who agreed that the new formulation smelled pleasant and was more effective than the original.
- PP2 was applied in the evening on two patients with neck stiffness who reported relief from stiffness and pain shortly thereafter. Patients remained at 0/10 pain the next morning and both stated they slept well, felt relaxed, and that their neck muscles rvere no longer stiff.
- PP3 w'as designed with an immediate-acting portion for instant pain relief, as well as a long-acting portion that would continually release bioactive substances such as the terpenoids, sesquiterpenes and flavonoids found inixie Chamomile Oil, German Chamomile Oil, Roman Chamomile Oil; as well as minerals, amino acids, and vitamins required for tissue repair.
- the long-acting portion may provide effects for at least 2-8 weeks (PMID 31618958).
- Naturally occurring micron-sized biosilicates such as Food Grade Diatomaceous Earth (FGDE) were contemplated for use in PP3. These biosilicates are already pre-fonned, do not require toxic chemicals to create, are chemically inert, are safely tolerated by living organisms for ingestion or topical application, have a large surface area for loading of pharmaceutically active compounds, thermostability, and most importantly safely serve as inert carriers of pharmaceutically active compounds without interfering with their native function (PMID 31618958).
- FGDE Food Grade Diatomaceous Earth
- hydrated biosilicates may be loaded with only one active compound; and a mixture of such singly loaded biosilicates may be considered depending on desired effect in target tissues.
- the design was to first create the long-acting portion, and then add the immediate- acting portion (including the anxiolytic), as these should be readily available for immediate effectiveness.
- An objective is to have immediate pain relief, as well as extended release of minerals, amino acids, vitamins, and bioactive plant flavonoids, terpenoids, sesquiterpenes, etc. which promote tissue regeneration and repair into the specific tissues that need it.
- the tissues will be directly supplied with raw? materials required for tissue formation and repair, facilitating healing and recovery?.
- PP3 could be made in multiple strengths (See Table 3 for sample recipes).
- mixtures prefferably admixed in a 15-mi dark-glass (e.g., green or blue as these are darker and protect from light) dropper bottle for precise drop by drop administration (vs a roller ball top, which would be difficult to quantify the amount used).
- a 15-mi dark-glass e.g., green or blue as these are darker and protect from light
- dropper bottle for precise drop by drop administration (vs a roller ball top, which would be difficult to quantify the amount used).
- Organic Chinese Licorice (glyeyrrhiza uralensis) (1-part Dry herb extracted in 3 parts water and mixed with vegetable glycerin Herbal Extract) 120 ml
- PP3.1 was applied sporadically (3x in 7 days) on a face for 2 weeks. After two applications, the patient noticed that the deep horizontal line across the bridge of the patient’s nose that the patient had for the past 10 years was no longer visible unless the patient wrinkled the nose on purpose; and that the enlarged pores on the T-zone (forehead, nose, chin) were significantly smaller, the skin surface itself was finer and more radiant. PP3.1 reduced wrinkles and pore size, and improved skin radiance and texture.
- Pluripotency is the ability to give rise to other cell types, depending on the signals in the cell’s microenvironment; thus, it is possible to regenerate neurons, blood vessels, connective tissues, and a variety of other cell types appropriate to the specific cell environment (See Figure 25).
- PP3.1 when PP3.1 is applied to the scalp it activates hair follicles to produce more hair, when applied to the skin it stimulates production of additional connective tissue (such as within a wrinkle) or additional skin cells.
- the local environmental signals within any given tissue will direct the induced pluripotent stem ceils to restore the tissue as needed.
- Signals within facial skin will direct production of more facial skin, while signals within the scalp will direct production of more foilicles/hair.
- scalp hairs growing on the face for example.
- Increasing the number of stem cells in the skin has a potential to promote youthfulness, decrease inflammation, and promote rapid wound healing as well as the formation of new skin. It shall be noted that there are endless applications for any topical preparation capable of creating inducible stem cells out of terminally differentiated skin cells, or any other cell to which it is applied. For example, in a patient with peripheral neuropathy it may be possible to regenerate neurons in the tissues underlying the skin where PP3.1 is applied. In a patient with a bum requiring new blood vessels, connective tissue and skin cells it may be possible to regenerate each of these. All that is required is being able to deliver PP3.1 or future iterations into the injured tissue.
- PP3.1 resulted in more rapid healing of blemishes as well as a brightening effect.
- the quality of a patient’s skin was more radiant, healthy, and vibrant.
- licorice root extract contains glabridin, which has been shown to inhibit melanogenesis and inflammation, as well as UBV-induced pigmentation (PMID 9870547). Coating the glabridin with the lipid mixture conferring skin penetrative properties delivered this into tissues leading to a skin-brightening effect.
- This preparation facilitates rapid healing by stimulating a stem cell response in the injured tissue, in addition to treating pain.
- Antimicrobial Blend 1, or AB1 which w3 ⁇ 4s previously made by the inventor to protect against colds/flu was admixed with PP3.1 in a 1 : 1 ratio and spread in a thin layer over the patient’s anterior right calf, and thickly over the wound site. A blow dryer was used diffusely for several minutes over the areas where the mixture was applied, to gently increase circulation ,
- Cinnamonum cassia 30 ml Cinnamon essential oil ( Cinnamonum cassia)
- Cinnamomum vera 5 nil Cinnamon Leaf essential oil ( Cinnamomum vera )
- Pain Preparation 4 incorporates the following designs and improvements, among others if desired.
- the main improvement here will be the addition of vegetable oils in proportions that will bring it closer to mimicking human skin/oil.
- mixtures should be admixed in a 15-m! dark-glass (preferably green or blue as these are darker and protect from light) dropper bottle for precise measurement.
- PP5 was prepared as follows:
- MNO+CO Macadamia Nut Oil + Coconut Oil Stock
- MNO+CO Macadamia Nut Oil + Coconut Oil Stock Mixture “MNO+CCJ’ [00299]
- MNO+CO mixture could be prepared as follows:
- Liquid skin could be prepared as follows.
- MNO+CO macadamia nut oil + coconut oil stock
- ABl is an antimicrobial formula with antibacterial, antifungal, and antiviral properties. Antibacterial properties are strongest, followed by antiviral, then antifungal. ABl could be prepared as follows:
- AB2 is an antimicrobial formula with wound healing, antibacterial, antifungal, and antiviral properties). AB2 could be prepared as follows:
- ABL2 is a dilute version of AB2.
- AB2 is diluted by 50% by doubling the carrier oil. It is more tolerable for those who are sensitive to strong smells and for children and elderly.
- Antimicrobial Blend 2 Breathe Formula [00306] is based on AB2 and includes additional ingredients to facilitate bronehodi!ation. It may be prepared as follows.
- ABIT is based on AB2 but include white thyme essential oil. 120 ml of white thyme essential oil is added to the formulation of AB2 for additional antiviral, antibacterial, and antifungal benefits.
- Antimicrobial Blend Extended-Release Formula (ABl ER - formulated with EDGE for extended release of active compounds)
- AB1 ER can be prepared as follows:
- Antimicrobial Blend Formula 1 (ABIJF1)
- ABUF1 has a high potency activity against bacteria, fungi, and viruses.
- ABUF1 can be prepared as follows:
- a 60-year-old female presented with sudden onset development of localized reddening, swelling, and purple patches on her fingers which spread from finger to finger of both hands for several weeks despite steroid creams prescribed by her dermatologists. She was unable to bend her fingers or use her hands due to the pain and swelling. After ruling out autoimmune and other differential diagnoses, biopsy showed she had vasculitis of unknown cause suspected to be COVID fingers as she met clinical criteria for COVID infection. After application of ABUF1 several times daily to her hands the swelling and pain decreased, allowing her to use her hands again without discomfort. The lesions stopped spreading, and by one week the lesions had faded. [00313] A 62-year-old F with a history of Raynaud’s phenomenon since her youth applied ABUF1 to her hands and noted relief from poor circulation, pain, and swelling of her hands upon application.
- ABF2 has high potency activity against bacteria, fungi, viruses and trypanosomes.
- ABF2 could be prepared as follows:
- AB1LY can he prepared as follows:
- AB1LY could be applied topically to reduce swelling.
- HYPFl can be prepared as follows:
- HYPFl could be applied topically to address headaches and other symptoms associated with hypertension while waiting for anti-hypertensive medications to work. Note the recommendations for dosing of wintergreen essential oil listed in Table 1.
- HDF1 could be prepared as follows:
- HDF1 could be applied topically to address headaches. Note the recommendations for dosing of wintergreen essential oil listed in Table 1.
- Relaxation/Sleep formula could be applied topically to the face, back of the neck and throat prior to bedtime.
- a topical formula that stimulates hair growth could be prepared as follows: 1. Pour 1 ⁇ 2 gallon of high oleic sunflower seed oil ::: 1893 ml into a 2L glass jar with lid
- a formulation for oral administration for gastrointestinal tract healing could be prepared as follows:
- Suppositories of this formula can also be made to treat internal hemorrhoids and can be applied topically to external hemorrhoids. This formulation should help stimulate regeneration of the mucosal lining.
- PC Phosphatidylcholine
- the chamomile mixture combined with the emu oil will further stimulate mucosal stem cells to regenerate and repair ulcerated and inflamed tissues while reducing inflammation, and the macadamia and coconut oils will provide essential components of the ceil membrane to repair a new gut lining,
- the formulation may be taken internally.
- INS1 is a formulation for treating insomnia, anxiety, and improve metabolism of fat.
- INS i could be prepared as follows:
- This spray can be administered intranasally up to 4 sprays per night, as the 300 meg dose of melatonin has been shown to sufficient to restore melatonin levels to that characteristic of healthy young patients, are the best tolerated, improve sleep, do not lead to daytime grogginess, and avoid desensitization of melatonin receptors (Wurtman et. al. Low Doses of Melatonin Promote sleep Onset and Maintenance in Older People - An Update US Neurology', 2014; 10(2): 117-9). Four sprays are allowed for loss of spray due to dripping.
- An eczema preparation in volume %, from about 15% to about 50% lino!eic acid; and from about 0,05% to about 50% by volume for each type of chamomile essential oil (Roman/German/Moroccan chamomile); and from about 0% to about 5% of orange oil may be prepared.
- the formulation includes hyaluronic acid at a concentration between 0.05%-60% by volume.
- C16: 1D6 fatty acids comprise between 5%-40% of the formulation by volume.
- the formulation may include full complement of 3 : 1 : 1 : 1 cholesterol, phospholipids, required to rebuild the skin barrier.
- a formulation for treatment of eczema and psoriasis may be prepared as follows:
- Psoriasis/Eczema/Wrinkles/Anti-aging Formula 2 PEWAF2
- PEWAF2 may be prepared as follows:
- PEWAF2 may be used for treatment of psoriasis, eczema, wrinkles and/or reducing/slowing down appearance of aging.
- PEWAF3 may be prepared as follows:
- myrrh + frankincense essential oil stock as follows: add 30 ml myrrh essential oil to 45 ml frankincense essential oil and mix well. Store in a dark glass bottle with dropper.
- PEW AFT may be used for treatment of particularly itchy psoriasis, eczema, insect bites and other itchy rashes.
- a kit comprises one or more formulation(s) according to the invention, a sealing/occlusive barrier cream, and a 100% organic cotton gloves, and a set of instructions. Instructions may, e.g., recommend patient to wash affected areas with lukewarm water, then pat skin with towel leaving skin moist: immediately apply hydrated hyaluronic acid mixed with Liquid Skin (1:1) blend first, then Eczema Preparation, then apply sealing/occlusive barrier cream, then wear gloves just prior to going to sleep.
- a conditioner may comprise l%-20% Roman/German/Moroccan essential oil by volume, and 1%-10% of Long- Acting Fraction (FGDE loaded biosilicates).
- FGDE loaded biosilicates An objective is to use it as a hair mask - lathering up but then letting it sit on the scalp to let the long-acting fraction soak into the scalp.
- the conditioner may soften and moisturize the scalp.
- the mask includes approximately 5%-70% of Long-Acting Fraction (FGDE loaded biosilicates) but may contain anywhere from 5x-30x more FGDE to ensure more loaded diatoms.
- the mask may be prepared as follows:
- the mask may be applied to face/scalp or other affected areas and allow to soak in for 30 minutes to 1 hour. Best used if resting under a near-infrared light to increase circulation and penetration (use of proper eye protection will be required).
- a face wash may comprise Liquid Skin with hyaluronic acid in a 1:1 ratio as a basic composition for a gentle cleanser, the basic composition may comprise between 10%-80% of the final product by volume.
- the face wash may include most, if not all, of components of Eczema Preparation(s) in the approximate percentages described above.
- the face wash does not include saponins and detergents, as they may worsens eczema.
- a spray comprising one or more formulation(s) of the invention may be prepared.
- the spray may be sprayed on the outside of a 3-ply surgical face mask (which may be worn over an N95 or KN95 without affecting the integrity of the N95 or KN95 mask), or may be sprayed on a cloth mask, e.g., to help with nausea for pregnant ladies, or to improve the mask- wearing experience.
- the spray may also have an additional benefit(s) of decreasing anxiety, improving mood, attention, and decreasing appetite.
- SMI Sweet Mint Spray
- MCT Medium Chain Triglycerides
- FMl Fresh Mint (FMl) Spray
- MCT Medium Chain Triglycerides
- FMl has a sharply spacious refreshing scent and may be sprayed with a spray vial, a mechanical pump or an aerosolized pump (e.g., 1-2 sprays) on the outside of any cloth or 3- ply surgical mask as described above.
- the spray should not be sprayed on N95 or KN95 masks, as oils degrade their ability to filter.
- LWS1 has a clean smelling, woodsy with citrus scent.
- LW81 may be prepared as follows.
- LWS1 may be sprayed with a spray vial, a mechanical pump or an aerosolized pump (e.g., 1-2 sprays) on the outside of any cloth or 3-ply surgical masks.
- the spray should not be sprayed on N95 or KN95 masks, as oils degrade their ability to filter.
- CFS1 has a clean smelling, light citrus, mint, spice, and a sweet grass scent.
- CFS1 may be prepared as follows:
- a 500 ml glass container mix 100 ml of organic Medium Chain Triglycerides (MCT) oil with 5 ml each of bergamot mint and gingergrass essential oils, and 1 ml of bergamot essential oil. Mix well, aliquot into 5 ml glass spray vials.
- CF81 may be sprayed with a spray vial, a mechanical pump or an aerosolized pump (e.g., 1-2 sprays) on the outside of any cloth or a 3 -ply surgical mask. The spray should not be sprayed on N95 or KN95 masks, as oils degrade their ability to filter.
- ISS 1 has a bright, uplifting, minty fresh citrus scent that produces an instant sensation of contentment, and may be prepared as follows:
- ISSl may be sprayed with a spray vial, a mechanical pump or an aerosolized pump (e.g., 1-2 sprays) on the outside of any cloth or a 3-ply surgical mask.
- the spray should not be sprayed on N95 or KN95 masks, as oils degrade their ability to filter.
- Formulations of the invention may be used to prepare a pest/insect control spray.
- the spray may comprise, e.g., plant-based essential oils.
- the essential oils may be selected such that they disinfect on contact, have a pleasant smell, and have antimicrobial (e.g., antifungal, antiviral and antibacterial) properties.
- the formulation is non-toxic to mammals and possesses beneficial properties as described in Table 1 but are toxic to invertebrates due to significant differences in vertebrate versus invertebrate physiology and anatomy.
- the formulation may provide beneficial effect(s) to humans, e.g., by virtue disinfecting the air and/or in direct contact of the aerosolized spray with nasal mucosa and/or skin.
- the formulation may inactivate insect neurologic systems by interfering with invertebrate cell membrane function, e.g., transport of nutrients and or air required for survival of an insect.
- the formulation may enter insect spiracules (breathing holes) and interfere with respiration in insects leading to their rapid demise.
- the formulation may be carried back to insect dwellings and additionally cause demise of eggs, larvae and juveniles.
- FDGE technology maybe used to provide a release of the formulation for an extended period of time.
- the formulations may comprise FDGE loaded with dead sea salts to form long-lasting microscopic crystals which extend release of volatile essential oils.
- formulations may be prepared as follows:
- the formulation was tested and found effective against ants, cockroaches, pill bugs, mosquitoes, flies and earwigs; and may be effective against other unlisted insects.
- the formulation may be used weekly, bi-weekly, every three weeks, or monthly depending on need.
- PP4, PP5 or subsequent PP formulations may be combined in 1 : 1 ratio with AB1 to provide a formulation for treatment of scar/keloids.
- Psoriasis/Eczema, as well as AB 1 formulations may also be used to treat scars/keloids.
- a 65 -year-old female also used the formulation and noted improvement to a dark brown keloid scar she’d had for over 5 years.
- the keloid which had initially measured approximately l/4”x 1/8” x 1/16” and was dark brown, had visibly flattened and lightened in color. With every application the keloid was noted to become smaller and flatter.
- HLD/NASH/WL1 may be prepared as follows:
- HLD/NASH/WL1 may be taken in liquid form or as capsules, but may be formulated for injection, infusion, or introduced via other routes. It may be taken alone or as part of a comprehensive weight loss plan to normalize lipid metabolism.
- NDGNF1 may be prepared as follows:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21760420.6A EP4110066A4 (en) | 2020-02-28 | 2021-02-26 | Formulations and uses thereof |
CN202180029930.8A CN115605092A (en) | 2020-02-28 | 2021-02-26 | Formulations and uses thereof |
KR1020227033068A KR20220148853A (en) | 2020-02-28 | 2021-02-26 | Formulations and uses thereof |
JP2022551670A JP2023516616A (en) | 2020-02-28 | 2021-02-26 | Formulations and their uses |
IL295102A IL295102A (en) | 2020-02-28 | 2021-02-26 | Formulations and uses thereof |
BR112022016789A BR112022016789A2 (en) | 2020-02-28 | 2021-02-26 | FORMULATIONS AND USES OF THEM |
MX2022010592A MX2022010592A (en) | 2020-02-28 | 2021-02-26 | Formulations and uses thereof. |
CA3169327A CA3169327A1 (en) | 2020-02-28 | 2021-02-26 | Formulations and uses thereof |
AU2021227936A AU2021227936A1 (en) | 2020-02-28 | 2021-02-26 | Formulations and uses thereof |
ZA2022/08636A ZA202208636B (en) | 2020-02-28 | 2022-08-02 | Formulations and uses thereof |
CONC2022/0012819A CO2022012819A2 (en) | 2020-02-28 | 2022-09-08 | Formulations and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062982918P | 2020-02-28 | 2020-02-28 | |
US62/982,918 | 2020-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021173933A1 true WO2021173933A1 (en) | 2021-09-02 |
Family
ID=77463244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/019821 WO2021173933A1 (en) | 2020-02-28 | 2021-02-26 | Formulations and uses thereof |
Country Status (14)
Country | Link |
---|---|
US (3) | US11801302B2 (en) |
EP (1) | EP4110066A4 (en) |
JP (1) | JP2023516616A (en) |
KR (1) | KR20220148853A (en) |
CN (1) | CN115605092A (en) |
AU (1) | AU2021227936A1 (en) |
BR (1) | BR112022016789A2 (en) |
CA (1) | CA3169327A1 (en) |
CL (1) | CL2022002312A1 (en) |
CO (1) | CO2022012819A2 (en) |
IL (1) | IL295102A (en) |
MX (1) | MX2022010592A (en) |
WO (1) | WO2021173933A1 (en) |
ZA (1) | ZA202208636B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116637107A (en) * | 2022-02-15 | 2023-08-25 | 四川大学 | Natural antioxidant-loaded antitumor nano-drug and load proportion screening method thereof |
CN115531256B (en) * | 2022-10-12 | 2023-08-04 | 植物医生(广东)生物科技有限公司 | Essential oil and preparation process thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110144142A1 (en) * | 2009-12-15 | 2011-06-16 | Mcneil-Ppc, Inc. | Methods of Reducing Hair Loss and/or Facilitating Hair Growth and/or Regrowth |
US20120171186A1 (en) * | 2009-05-25 | 2012-07-05 | Woon San Liang | method for producing a nutraceutical composition and the nutraceutical produced by the method |
US20130171078A1 (en) * | 2011-06-30 | 2013-07-04 | Clement Lawson | Transfer Resistant Cosmetic Composition |
WO2013186108A2 (en) * | 2012-06-15 | 2013-12-19 | L'oreal | Method for mattifying oily skin |
US20170360073A1 (en) * | 2014-11-07 | 2017-12-21 | Jolly Mathew Vadakkemuri | Optimized nutrient fatty acid composition |
US20190053996A1 (en) * | 2014-12-03 | 2019-02-21 | Mary Kay Inc. | Cosmetic composition and methods of use thereof |
US20200000693A1 (en) * | 2018-06-27 | 2020-01-02 | CoLabs International Corporation | Compositions Comprising Silicon Dioxide-Based Particles Including One or More Agents |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9704904D0 (en) | 1997-03-10 | 1997-04-30 | Riley Fletcher Foundation The | Essential oil composition |
EP1274472A2 (en) | 2000-03-20 | 2003-01-15 | Biosphere Medical, Inc. | Injectable and swellable microspheres for tissue bulking |
IT1317911B1 (en) * | 2000-09-28 | 2003-07-15 | Idi Irccs | COSMETIC FORMULATION. |
FR2831442B1 (en) * | 2001-10-30 | 2005-02-11 | Oreal | COSMETIC COMPOSITION MIMING THE SEBUM, AND USES THEREOF |
US20040185115A1 (en) | 2002-05-17 | 2004-09-23 | Maurine Pearson | Emu oil based methods and compositions for skin ailments |
US7029711B2 (en) * | 2003-12-09 | 2006-04-18 | Shannon Lynn Farrell | Mixture of and method of making a trancutaneous pain relief composition |
EP1866397A2 (en) | 2005-03-29 | 2007-12-19 | Arizona Chemical Company | Compostions containing fatty acids and/or derivatives thereof and a low temperature stabilizer |
US20080311613A1 (en) * | 2007-06-14 | 2008-12-18 | The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services | Artificial skin surface film liquids |
US8343468B2 (en) * | 2009-10-26 | 2013-01-01 | International Flora Technologies, Ltd. | Human sebum mimetics derived from botanical sources and methods for making the same |
US8765106B2 (en) * | 2009-10-26 | 2014-07-01 | International Flora Technologies, Ltd. | Human sebum mimetics derived from botanical sources and methods for making the same |
US8268364B1 (en) * | 2010-02-19 | 2012-09-18 | Mintiva Holdings LLC | Water based pain relieving composition |
EP2667945A1 (en) | 2011-01-24 | 2013-12-04 | Anterios, Inc. | Oil compositions |
US9138446B2 (en) | 2011-06-08 | 2015-09-22 | Scott Alan Weisenfluh | EMU oil in combination with other active ingredients for treating skin imperfections |
CN102628002A (en) * | 2012-03-31 | 2012-08-08 | 华健 | Preparation process for prinsepia utilis royle grease |
US9566306B2 (en) | 2012-04-16 | 2017-02-14 | Zemtsov Enterprises, Llc | Formulations and methods for treatment of wounds and inflammatory skin conditions |
EP2892502A4 (en) * | 2012-09-05 | 2015-09-02 | Int Flora Technologies Ltd | Human sebum mimetics derived from botanical sources and methods for making the same |
CN103536473A (en) * | 2013-10-17 | 2014-01-29 | 苏州威尔德工贸有限公司 | Hydrating smoothing toner |
CN104651087A (en) * | 2015-02-09 | 2015-05-27 | 福建美力生生物科技股份有限公司 | Flaxseed oil handmade soap |
CN108379126A (en) * | 2018-04-26 | 2018-08-10 | 广东岭南职业技术学院 | A kind of fat of Oromaius norvaehollandeae cold cream and preparation method thereof |
CN109846757B (en) * | 2019-02-15 | 2022-01-11 | 广州环亚化妆品科技有限公司 | Sebum biomimetic composition and cosmetic containing same |
-
2021
- 2021-02-26 IL IL295102A patent/IL295102A/en unknown
- 2021-02-26 US US17/186,548 patent/US11801302B2/en active Active
- 2021-02-26 CA CA3169327A patent/CA3169327A1/en active Pending
- 2021-02-26 WO PCT/US2021/019821 patent/WO2021173933A1/en active Application Filing
- 2021-02-26 BR BR112022016789A patent/BR112022016789A2/en unknown
- 2021-02-26 KR KR1020227033068A patent/KR20220148853A/en unknown
- 2021-02-26 EP EP21760420.6A patent/EP4110066A4/en active Pending
- 2021-02-26 JP JP2022551670A patent/JP2023516616A/en active Pending
- 2021-02-26 AU AU2021227936A patent/AU2021227936A1/en active Pending
- 2021-02-26 CN CN202180029930.8A patent/CN115605092A/en active Pending
- 2021-02-26 MX MX2022010592A patent/MX2022010592A/en unknown
- 2021-09-07 US US17/467,976 patent/US11801303B2/en active Active
-
2022
- 2022-08-02 ZA ZA2022/08636A patent/ZA202208636B/en unknown
- 2022-08-24 CL CL2022002312A patent/CL2022002312A1/en unknown
- 2022-09-08 CO CONC2022/0012819A patent/CO2022012819A2/en unknown
-
2023
- 2023-08-29 US US18/239,195 patent/US20230405126A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120171186A1 (en) * | 2009-05-25 | 2012-07-05 | Woon San Liang | method for producing a nutraceutical composition and the nutraceutical produced by the method |
US20110144142A1 (en) * | 2009-12-15 | 2011-06-16 | Mcneil-Ppc, Inc. | Methods of Reducing Hair Loss and/or Facilitating Hair Growth and/or Regrowth |
US20130171078A1 (en) * | 2011-06-30 | 2013-07-04 | Clement Lawson | Transfer Resistant Cosmetic Composition |
WO2013186108A2 (en) * | 2012-06-15 | 2013-12-19 | L'oreal | Method for mattifying oily skin |
US20170360073A1 (en) * | 2014-11-07 | 2017-12-21 | Jolly Mathew Vadakkemuri | Optimized nutrient fatty acid composition |
US20190053996A1 (en) * | 2014-12-03 | 2019-02-21 | Mary Kay Inc. | Cosmetic composition and methods of use thereof |
US20200000693A1 (en) * | 2018-06-27 | 2020-01-02 | CoLabs International Corporation | Compositions Comprising Silicon Dioxide-Based Particles Including One or More Agents |
Non-Patent Citations (2)
Title |
---|
See also references of EP4110066A4 * |
WARNER K., MOUNTS T. L.: "FRYING STABILITY OF SOYBEAN AND CANOLA OILS MODIFIED FATTY ACID COMPOSITIONS.", JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, SPRINGER, DE, vol. 70, no. 10, 1 October 1993 (1993-10-01), DE, pages 983 - 988, XP000403776, ISSN: 0003-021X, DOI: 10.1007/BF02543024 * |
Also Published As
Publication number | Publication date |
---|---|
ZA202208636B (en) | 2023-11-29 |
US20230000987A1 (en) | 2023-01-05 |
US11801303B2 (en) | 2023-10-31 |
IL295102A (en) | 2022-09-01 |
US11801302B2 (en) | 2023-10-31 |
KR20220148853A (en) | 2022-11-07 |
EP4110066A1 (en) | 2023-01-04 |
AU2021227936A1 (en) | 2022-09-01 |
EP4110066A4 (en) | 2024-04-17 |
CL2022002312A1 (en) | 2023-04-21 |
JP2023516616A (en) | 2023-04-20 |
US20210268110A1 (en) | 2021-09-02 |
BR112022016789A2 (en) | 2022-10-11 |
MX2022010592A (en) | 2023-01-11 |
US20230405126A1 (en) | 2023-12-21 |
CN115605092A (en) | 2023-01-13 |
CA3169327A1 (en) | 2021-09-02 |
CO2022012819A2 (en) | 2022-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Weis et al. | An overview about apitherapy and its clinical applications | |
US20230405126A1 (en) | Formulations and uses thereof | |
JP6983160B2 (en) | A composition comprising ambora extract and green tea extract for the treatment of psoriasis, atopic dermatitis, chronic urticaria, antihistamine-resistant pruritus, and senile pruritus. | |
US20070264222A1 (en) | Enhanced protection against skin injury in humans | |
US20190151232A1 (en) | Topical Compositions, Process of Manufacture and Method of Use | |
KR20200029981A (en) | Composition for Prevention or Improving of Atopic Dermatitis and manufacturing method thereof | |
JP2010059161A (en) | Composition for makeup or skin disease containing mixture of essential oil and its use especially for care for sensitive skin or sensitized skin | |
US20090232904A1 (en) | Homeopathic Skin Care Compositions and Uses Thereof | |
JP5622775B2 (en) | Composition for treating dermatosis, formulation using the same, and preparation method thereof | |
KR102220534B1 (en) | Soothing cream and manufacturing method for the same | |
KR20170112745A (en) | Cosmetic composition for improving acne containing teatree leaves spicule powder | |
KR20040055713A (en) | Composition and Preparing Method of Lotion which include Essential Oil Blend for Healing Mental Problem | |
Dickinson et al. | Rolling Stone | |
US20150238462A1 (en) | Composition comprising plant phenols for preventing or reducing tewl and associated disorders and diseases | |
Stiles | The essential oils complete reference guide: Over 250 recipes for natural wholesome aromatherapy | |
CN101791285B (en) | Clausenamide composite nanometer emulsion for clearing facial age pigment (lipofuscin) and preparation method thereof | |
CN110974861B (en) | Blumea balsamifera oil liposome | |
CN101332302B (en) | Formula for preparing anti-eczema and cutitis products and preparation method thereof | |
US20220273015A1 (en) | Formulations and uses thereof | |
CN107582783B (en) | Nasal cavity isolation paste for preventing and treating allergic rhinitis and preparation method and application thereof | |
KR102217697B1 (en) | Aromatherapy composition comprising natural aroma oil | |
KR100190233B1 (en) | Composition for hair treatment | |
RU2763171C1 (en) | Method for producing an emulsion containing nano- and microencapsulated biologically active substances | |
RU2282473C2 (en) | Curative-prophylactic pomade eliciting antiviral activity and method for its preparing | |
Axe et al. | The Beginner's Guide to Essential Oils: Ancient Medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21760420 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3169327 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022551670 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022016789 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021227936 Country of ref document: AU Date of ref document: 20210226 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227033068 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021760420 Country of ref document: EP Effective date: 20220928 |
|
ENP | Entry into the national phase |
Ref document number: 112022016789 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220823 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522440299 Country of ref document: SA |